0001213900-23-039043.txt : 20230512 0001213900-23-039043.hdr.sgml : 20230512 20230512162156 ACCESSION NUMBER: 0001213900-23-039043 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bio Essence Corp CENTRAL INDEX KEY: 0001723059 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943349551 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56263 FILM NUMBER: 23916135 BUSINESS ADDRESS: STREET 1: 8 STUDEBAKER DRIVE CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-706-9966 MAIL ADDRESS: STREET 1: 8 STUDEBAKER DRIVE CITY: IRVINE STATE: CA ZIP: 92618 10-Q 1 f10q0323_bioessen.htm QUARTERLY REPORT

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

OR

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 333-232839

 

 

 

BIO ESSENCE CORP.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

 

California

(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)

 

94-3349551

(IRS EMPLOYEE IDENTIFICATION NO.)

 

8 Studebaker Drive in Irvine, California 92618

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

(949) 706-9966

(ISSUER TELEPHONE NUMBER)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
  Emerging Growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Exchange on Which Registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of the latest practicable date, the Company has 33,009,000 shares of its common stock issued and outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS 

 

    PAGE
PART I FINANCIAL INFORMATION
     
Item 1. Financial Statements  
  Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022 1
  Statements of Operations for three months ended March 31, 2023 and 2022 (Unaudited) 2
  Statements of Changes in Stockholders’ Equity for three months ended March 31, 2023 and 2022 (Unaudited) 3
  Statements of Cash Flows for three months ended March 31, 2023 and 2022 (Unaudited) 4
  Notes to Financial Statements (Unaudited) 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
Item 3. Quantitative and Qualitative Disclosures About Market Risk 20
Item 4. Controls and Procedures 20
     
PART II   22
     
Item 1. Legal Proceedings 22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22
Item 3. Defaults Upon Senior Securities 22
Item 4. Mine Safety Disclosures 22
Item 5. Other Information 22
Item 6. Exhibits 22
  Signatures 23

 

i

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   AS OF   AS OF 
   MARCH 31, 2023   DECEMBER 31, 2022 
ASSETS  (UNAUDITED)     
         
CURRENT ASSETS        
Cash and equivalents  $127   $6,262 
Accounts receivable, net   10,700    5,599 
Prepaid expenses   8,630    8,820 
Advance to suppliers   61,573    1,987 
Inventory, net (Note 3)   172,745    181,163 
           
Total current assets   253,775    203,831 
           
NONCURRENT ASSETS          
Security deposit (Note 4)   41,841    41,841 
Right-of-use assets, net   1,015,457    1,054,872 
Property and equipment, net (Note 5)   230,036    246,379 
Intangible assets, net (Note 6)   744    802 
           
Total non-current assets   1,288,078    1,343,894 
           
TOTAL ASSETS  $1,541,853   $1,547,725 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
Bank overdraft  $70,860   $53,651 
Accounts payable   58,334    49,776 
Taxes payable (Note 7)   12,899    8,392 
Accrued liabilities and other payables (Note 8)   67,118    91,645 
Accrued interest on government loans   16,805    16,867 
Operating lease liabilities (Note 12)   160,176    156,560 
Finance lease liabilities (Note 12)   12,761    12,603 
Loan payables (Note 13)   12,311    11,954 
Government loans payable - current portion (Note 9)   4,639    4,596 
Loan from shareholder (Note 10)   3,367,397    3,151,786 
           
Total current liabilities   3,783,300    3,557,830 
           
NONCURRENT LIABILITIES          
Operating lease liabilities (Note 12)   908,040    952,756 
Finance lease liabilities (Note 12)   36,335    39,687 
Loan payables (Note 13)   22,236    25,561 
Government loans payable (Note 9)   209,193    210,306 
           
Total non-current liabilities   1,175,804    1,228,310 
           
TOTAL LIABILITIES   4,959,104    4,786,140 
           
COMMITMENTS AND CONTINGENCIES   
-
    
-
 
           
STOCKHOLDERS’ DEFICIT          
Preferred stock $0.0001 par value; authorized shares 10,000,000   
-
    
-
 
Common stock $0.0001 par value; authorized shares 100,000,000; issued and outstanding shares 33,009,000 as of March 31, 2023 and December 31, 2022   3,301    3,301 
           
Additional paid in capital   4,926,879    4,926,879 
Accumulated deficit   (8,347,431)   (8,168,595)
           
TOTAL STOCKHOLDERS’ DEFICIT   (3,417,251)   (3,238,415)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $1,541,853   $1,547,725 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

1

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   FOR THE THREE
MONTHS ENDED
MARCH 31,
 
   2023   2022 
         
Revenues        
Sales of goods  $149,760   $181,579 
Manufacture service revenue   191,569    124,835 
Total revenues   341,329    306,414 
           
Cost of revenues          
Cost of goods sold   70,500    145,665 
Cost of manufacture service   104,307    90,293 
Total cost of revenues   174,807    235,958 
           
Gross profit   166,522    70,456 
           
Operating expenses          
Selling   35,712    10,614 
General and administrative   304,994    286,274 
           
Total operating expenses   340,706    296,888 
           
Loss from operations   (174,184)   (226,432)
           
Other income (expenses)          
Interest expense   (5,824)   (5,160)
Financial expense   (976)   (1,568)
Other income   2,497    535 
Other expense   (349)   (495)
           
Other expenses, net   (4,652)   (6,688)
           
Loss before income tax   (178,836)   (233,120)
           
Income tax expense   
-
    
-
 
           
Net loss  $(178,836)  $(233,120)
           
Basic and diluted weighted average shares outstanding
   33,009,000    33,009,000 
           
Basic and diluted net loss per share
  $(0.01)  $(0.01)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

   COMMON   COMMON   ADDITIONAL          
   STOCK -
SHARES
   STOCK -
AMOUNT
   PAID IN
CAPITAL
   ACCUMULATED
DEFICIT
   TOTAL 
                     
Balance at January 1, 2023   33,009,000   $3,301   $4,926,879   $(8,168,595)  $(3,238,415)
                        - 
Net loss   -    
-
    
-
    (178,836)   (178,836)
                        - 
Balance at March 31, 2023   33,009,000   $3,301   $4,926,879   $(8,347,431)  $(3,417,251)
                          
Balance at January 1, 2022   33,009,000   $3,301   $4,926,879   $(7,358,916)  $(2,428,736)
                          
Net loss   -    -    -    (233,120)   (233,120)
                          
Balance at March 31, 2022   33,009,000   $3,301   $4,926,879   $(7,592,036)  $(2,661,856)

  

The accompanying notes are an integral part of these consolidated financial statements.

  

3

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   FOR THE THREE
MONTHS ENDED
MARCH 31,
 
   2023   2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss  $(178,836)  $(233,120)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   16,401    10,874 
Operating lease expense   53,110    57,717 
Increase (decrease) in assets:   Changes in assets / liabilities:          
Accounts receivable   (5,103)   (31,539)
Prepaid expenses   190    (5,536)
Advance to suppliers   (59,586)   (10,636)
Inventory   8,419    (45,442)
Accounts payable   8,558    28,291 
Customer deposit   (29,264)   
-
 
Accrued liabilities and other payables   4,738    27,804 
Accrued interest   (62)   
-
 
Taxes payable   4,507    4,319 
Payment on lease liabilities   (54,795)   (57,207)
           
Net cash used in operating activities   (231,723)   (254,475)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Bank overdraft   17,209    8,367 
Repayment of finance lease liabilities   (3,193)   
-
 
Repayment of government loans   (1,071)   
-
 
Repayment of loan payables   (2,968)   (3,970)
Loan from shareholder   215,611    250,000 
           
Net cash provided by financing activities   225,588    254,397 
           
NET DECREASE IN CASH & EQUIVALENTS   (6,135)   (78)
           
CASH & EQUIVALENTS, BEGINNING OF PERIOD   6,262    303 
           
CASH & EQUIVALENTS, END OF PERIOD  $127   $225 
           
Supplemental Cash Flow Data:          
Income tax paid  $
-
   $
-
 
Interest paid  $5,883   $6,098 
           
Supplemental disclosures of non-cash financing activities:          
Fixed assets obtained in exchange for new finance lease liabilities  $
-
   $16,077 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4

 

 

BIO ESSENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023 (UNAUDITED) AND DECEMBER 31, 2022

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Bio Essence Corporation (“the Company” or “Bio Essence”) was incorporated in 2000 in the state of California. Fusion Diet Systems (“FDS”) was incorporated in 2010 in the state of Utah. Bio Essence and FDS were under common control since 2016. Bio Essence and FDS are mainly engaged in manufacturing and distributing health supplement products. In January 2017, Bio Essence incorporated two subsidiaries in the state of California: Bio Essence Pharmaceutical Inc. (“BEP”) and Bio Essence Herbal Essentials, Inc. (“BEH”), Bio Essence transferred its manufacturing operation to BEP, and transferred its distributing operation to BEH. On March 1, 2017, the 100% shareholder of FDS transferred all of her ownership in FDS to Bio Essence. On December 7, 2021, the Company dissolved FDS. On November 12, 2021, Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in developing, manufacturing and sales of prescription medicine. As a result of the ownership restructure, BEP BEH and McBE became wholly owned subsidiaries of Bio Essence. McBE has not engaged any operations since its inception.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Consolidation

 

The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation.

 

The interim consolidated financial information as of March 31, 2023 and for the three-month periods ended March 31 30, 2023 and 2022 was prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures, which are normally included in CFS prepared in accordance with U.S. GAAP were not included. The interim consolidated financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of March 31, 2023, its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022, as applicable, were made. The results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2023 or for any future period.

 

Reclassification

 

Certain prior period accounts have been reclassified in conformity with current period’s presentation. These reclassifications had no impact on the reported results of operations and cash flows.

 

Going Concern

 

The Company incurred net losses of $178,836 and $233,120 for the three months ended March 31, 2023 and 2022, respectively. The Company also had an accumulated deficit of $8,347,431 as of March 31, 2023. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

5

 

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Leases

 

The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s consolidated balance sheets.

 

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

The Company elected the package of practical expedients permitted under the transition guidance to combine the lease and non-lease components as a single lease component for operating leases associated with the Company’s office space lease, and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.

 

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. The Company recognized no impairment of ROU assets as of March 31, 2023 and December 31, 2022.

 

Cash and Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2023 and December 31, 2022, the bad debt allowance was $2,252 and $2,252, respectively.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value with cost determined on a weighted-average basis. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down their inventories to net realizable value, if lower.

 

6

 

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets as follows:

 

Leasehold improvements   7-10 years
Office furniture   5  years

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

 

Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of March 31, 2023 and December 31, 2022, there was no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets also include the prior years’ net operating losses carried forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

At March 31, 2023 and December 31, 2022, the Company did not take any uncertain positions that would necessitate recording a tax related liability. The Company files a U.S. income tax return. With few exceptions, the Company’s U.S. income tax return filed for the years ending on December 31, 2019 and thereafter are subject to examination by the relevant taxing authorities.


The Company accounts for income taxes in interim periods in accordance with FASB ASC 740-270, “Interim Reporting.” The Company has determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during the Company’s fiscal year to its best current estimate. The estimated annual effective tax rate is applied to the year-to-date ordinary income (or loss) at the end of the interim period.

 

7

 

 

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

 

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.

 

Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the manufactured goods were delivered to the customers.

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2023 and 2022.

 

Cost of Revenue

 

Cost of goods sold (“COGS”) consists primarily of finished goods purchased from other manufacturers, material costs, labor costs and related overhead that are directly attributable to the production of the products. Write-down of inventory to lower of cost or net realizable value is also recorded in COGS.

 

Cost of manufacture service consists primarily of direct labor costs and related overhead that are directly attributable to the manufacture process.

 

Shipping and Handling Costs

 

Shipping and handling costs related to delivery of finished goods are included in selling expenses. During the three months ended March 31, 2023 and 2022, shipping and handling costs were $9,416 and $9,340, respectively.

 

Advertising

 

Advertising expenses consist primarily of costs of promotion and marketing for the Company’s image and products, and costs of direct advertising, and are included in selling expenses. The Company expenses all advertising costs as incurred. During the three months ended March 31, 2023 and 2022, advertising expense was $5,400 and $1,274, respectively.

 

Fair Value (“FV”) of Financial Instruments

 

Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

8

 

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:

 

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.

 

As of March 31, 2023 and December 31, 2022, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV. The carrying value of cash, accounts receivable, prepaid expenses, advances to suppliers, accounts payable, taxes payable, other payables and accrued liabilities approximate estimated fair values because of their short maturities.

 

Share-based Compensation

 

The Company accounts for share-based compensation awards in accordance with ASC 718, “Compensation – Stock Compensation”. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date and amortized on a straight-line basis over the requisite service period or vesting period. The Company records forfeitures as they occur.

 

Earnings (Loss) per Share (EPS)

 

Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed similar to basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if all the potential common shares pertaining to warrants, stock options, and similar instruments had been issued and if the additional common shares were dilutive. Diluted EPS are based on the assumption that all dilutive convertible shares and stock options and warrants were converted or exercised. Dilution is computed by applying the treasury stock method for the outstanding unvested restricted stock, options and warrants, and the if-converted method for the outstanding convertible instruments. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later) and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, outstanding convertible instruments are assumed to be converted into common stock at the beginning of the period (or at the time of issuance, if later). There were no potentially dilutive securities outstanding (options and warrants) for the three months ended March 31, 2023 and 2022.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.

 

For the three months ended March 31, 2023, the company had one major customer accounted for 34% of the Company’s total sales. For the three months ended March 31, 2022, the company had one major customer accounted for 27% of the Company’s total sales.

 

The Company had three major vendors accounted for 22%, 20%, and 17% respectively, of total purchases during the three months ended March 31, 2023. The Company had four major vendors accounted for 23%, 19%, 10% and 10%, respectively, of total purchases during the three months ended March 31, 2022.

 

9

 

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: manufacture and sale of health supplement products.

 

New Accounting Pronouncements

 

Recently issued accounting pronouncements not yet adopted

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company is currently evaluating the impact that ASU 2020-06 may have on its CFS and related disclosures.

 

3. INVENTORY

 

Inventory consisted of the following at March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Raw materials  $57,438   $60,705 
Finished goods – health supplements   141,425    146,576 
Less: inventory impairment allowance   (26,118)   (26,118)
Total  $172,745   $181,163 

 

4. SECURITY DEPOSIT

 

As of March 31, 2023 and December 31, 2022, the security deposit was for rent of the Company’s office and warehouse of $41,841.

 

10

 

 

5. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Leaseholder improvements  $57,067   $57,067 
Office furniture and equipment   406,241    406,241 
Total   463,308    463,308 
Less: accumulated depreciation   (233,272)   (216,929)
Net  $230,036   $246,379 

 

Depreciation for the three months ended March 31, 2023 and 2022 was $16,342 and $10,815, respectively.

 

6. INTANGIBLE ASSETS, NET

 

Intangible assets consisted of the following as of March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Computer Software  $36,928   $36,928 
Trademark   2,350    2,350 
Total   39,278    39,278 
Less: accumulated amortization   (38,534)   (38,476)
Net  $744   $802 

 

Amortization of intangible assets was $59 and $6,349 for the three months ended March 31, 2023 and 2022, respectively.

 

Estimated amortization for the existing intangible assets with finite lives for each of the next five years at March 31, 2023 is as follows: $235, $235, $235 and $39.

 

7. TAXES PAYABLE

 

Taxes payable at March 31 2023, and December 31, 2022, was for sales tax and payroll tax payable of $12,899 and $8,392, respectively.

 

8. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Accrued expenses  $6,810   $6,756 
Credit card payable   43,960    39,277 
Customer deposit   16,348    45,612 
           
Total  $67,118   $91,645 

 

11

 

 

9. GOVERNMENT LOANS PAYABLE

 

In May and June 2020, BEH, BEP and FDS received a total of $127,740 from the Paycheck Protection Program loan (“PPP loan”) from US Small Business Administration (“the SBA”). The loan will be fully forgiven if the funds are used for payroll costs, interest on mortgages, rent, and utilities (at least 60% of the forgiven amount must have been used for payroll). The loan amount not forgiven, will have annual interest of 1%. Loan payments will be deferred to either (1) the date that SBA remits the borrower’s loan forgiveness amount to the lender or (2) if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness covered period. Loans issued prior to June 5, 2020 have a maturity of two years, loans issued after June 5, 2020 have a maturity of five years. No collateral or personal guarantees are required. A borrower may apply for loan forgiveness any time on or before the maturity date of the loan, including before the end of the Covered Period (either (1) the 24-week (168-day) period beginning on the PPP Loan Disbursement Date, or (2) if the Borrower received its PPP loan before June 5, 2020, the Borrower may elect to use an eight-week (56-day) Covered Period); provided such application for loan forgiveness is made within 10 months after the last day of the covered period, otherwise the loan is no longer deferred and the borrower must begin paying principal and interest. Subsequently, The U.S. Treasury and SBA announced a streamlined PPP forgiveness application for loans of $50,000 or less (unless those borrowers together with their affiliates received loans totaling $2 million or more). It requires fewer calculations and may call for less documentation. It does not require borrowers to reduce their loan forgiveness calculations if they have reduced full-time equivalent (“FTE”) or salaries. In addition, in February 2021, BEH, BEP and FDS received a total of $115,245 from the second round of PPP loan from the SBA. As of December 31, 2021, all BEH, BEP and FDS’ PPP loans’ forgiveness were approved and the Company recorded $242,985 PPP loan forgiveness as other income in the year ended December 31, 2021.

 

In May and June 2020, BEH, BEP and FDS received total of $215,600 from the Economic Injury Disaster Loan (“EIDL loan”) from the SBA after deducting $100 Uniform Commercial Code (“UCC”) handling charge and filing fee for each company. This is a low-interest federal disaster loan for working capital to small businesses and non-profit organizations of any size suffering substantial economic injury as a result of the Coronavirus (COVID-19), to help the businesses to meet financial obligations and operating expenses that could have been met had the disaster not occurred. This loan has interest of 3.75% and is not forgivable. The maturity of the loan is 30 years, installment payments including principal and interest of $515 monthly will begin 12 months from the date of the promissory note. On March 4, 2022, The FDS transferred its EIDL loan to BEC due to the dissolution of FDS. The SBA extended the deferment period to allow small businesses and not-for-profits that received EIDL funds do not have to begin payments on the loan until 30 months after the date of the note. Accordingly, the company began to make installment payments in the fourth quarter 2022.

 

As of March 31, 2023, the future minimum EIDL loan payments to be paid by year are as follows:

 

Year Ending  Amount 
   (unaudited) 
     
March 31, 2024  $4,639 
March 31, 2025   4,816 
March 31, 2026   5,000 
March 31, 2027   5,191 
March 31, 2028   5,389 
Thereafter   188,797 
Total  $213,832 

 

10. RELATED PARTY TRANSACTIONS

 

Loans from Shareholder

 

At March 31, 2023 and December 31, 2022, the Company had loans from one major shareholder (also the Company’s senior officer) for $2,758,766 and $2,543155, respectively. At March 31, 2023 and December, 2022, the Company had loan from another major shareholder for $608,631 for settling the litigation. There are no written loan agreements for these loans. These loans are unsecured, non-interest bearing and have no fixed terms of repayment, and therefore, deemed payable on demand. Cash flows from loans form shareholder are classified as cash flows from financing activities.

 

12

 

 

11. INCOME TAXES

 

The Company and its subsidiaries are subject to 21% federal corporate income tax in US.

 

At March 31, 2023 and December, 2022, the Company had net operating loss (“NOL”) for income tax purposes; for federal income tax purposes, the NOL arising in tax years beginning after 2017 may only reduce 80% of a taxpayer’s taxable income, and may be carried forward indefinitely; for California income tax purposes, the entire NOL can be carried forward up to 20 years. However, the coronavirus Aid, Relief and Economic Security Act (“the CARES Act”) issued in March 2020, provides tax relief to both corporate and noncorporate taxpayers by adding a five-year carryback period and temporarily repealing the 80% limitation for NOLs arising in 2019, 2020 and 2021.

 

The Company has NOL carry-forwards for Federal and California income tax purposes of $5.42 million and $5.25 million at March 31, 2023 and December 31, 2022, respectively. No tax benefit was reported with respect to these NOL carry-forwards in the accompanying consolidated financial statements because the Company believes the realization of the Company’s net deferred tax assets for the NOL for both federal and California State of approximately $1.52 million as of March 31, 2023, was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are fully offset by a full valuation allowance.

 

Components of the Company’s deferred tax assets as of March 31, 2023 and December 31, 2022 are as follows:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
Net deferred tax assets:        
Bad debt expense  $1,978   $1,978 
Inventory impairment   697    697 
Operating lease charge   13,596    14,020 
Depreciation and amortization   237    237 
Expected income tax benefit from NOL carry-forwards   1,517,801    1,467,801 
Less: valuation allowance   (1,534,309)   (1,484,733)
Deferred tax assets, net of valuation allowance  $
-
   $
-
 

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the consolidated federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes for the three months ended March 31, 2023 and 2022 is as follows:

 

   2023   2022 
   (unaudited)   (unaudited) 
Federal statutory income tax expense (benefit) rate   (21.00)%   (21.00)%
State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax   (6.98)%   (6.98)%
Change in valuation allowance   27.98%   27.98%
Effective income tax rate   
-
%   
-
%

 

The provision for income tax expense for the three months ended March 31, 2023 and 2022 consisted of the following:

 

   2023   2022 
   (unaudited)   (unaudited) 
Income tax expense – current  $
-
   $
-
 
Income tax benefit – current   
-
    
-
 
Total income tax expense  $
        
   $
       
 

 

13

 

 

12. LEASES

 

Operating Leases

 

Warehouse and office lease

 

Effective October 1, 2018, the Company entered a 62.5 months lease for a facility including warehouse and office in the City of Irvine, California, with a security deposit of $41,841. The monthly rent is approximately $16,200 with a 3% increase each year. The lease provided an option to extend at lease maturity for another five-years, with six months prior written notice of lessee’s intention to extend the lease. The Company’s CEO is the guarantor of this lease. Lessor will have the right to proceed against guarantor following any breach or default by lessee without first proceeding against lessee and without previous notice to or demand upon either lessee or guarantor.

 

The components of lease costs, lease term and discount rate with respect of warehouse and office lease in the City of Irvine with an initial term of more than 12 months are as follows:

 

   Three Months Ended
March 31,
2023
   Three Months Ended
March 31,
2022
 
   (unaudited)   (unaudited) 
Operating lease cost  $53,281   $53,281 
Weighted Average Remaining Lease Term - Operating leases including options to renew   5.51 years    6.51 years 
Weighted Average Discount Rate - Operating leases   5%   5%

 

The following is a schedule, by years, of maturities of warehouse and office lease liabilities as of March 31, 2023:

 

For the 12 months ending  Operating
Leases
 
   (unaudited) 
March 31, 2024  $205,848 
March 31, 2025   225,757 
March 31, 2026   225,757 
March 31, 2027   225,757 
March 31, 2028   225,757 
Thereafter   112,876 
Total undiscounted cash flows   1,221,752 
Less: imputed interest   (153,535)
Present value of lease liabilities  $1,068,217 

 

Equipment leases

 

In 2017, the Company entered two leases for two copiers with terms of 60 and 63 months respectively, and monthly payments of $162 and $213, respectively. The Company also entered two leases for two forklifts with a term of 60 months for each, and the monthly payment was $292 and $669, respectively. All these equipment lease expired in 2022.

 

The components of lease costs, lease term and discount rate with respect of these equipment leases are as follows:

 

   Three Months Ended
March 31,
2023
   Three Months Ended
March 31,
2022
 
   (unaudited)   (unaudited) 
Operating lease cost  $0.00   $4,008 
Weighted Average Remaining Lease Term - Operating leases   0.00 years    0.19 years 
Weighted Average Discount Rate - Operating leases   5%   5%

 

14

 

 

Finance lease

 

Effective March 15, 2022, the company entered two 39-months lease for two copiers with same vendor for a monthly payment of $234 and $214, respectively. Effective June 24, 2022, the company entered two leases for two forklifts with a term of 60 months for each, and the monthly payment was $383 and $451, respectively. At the lease expiration date, the Company has the option to purchase the copier for $1 each.

 

The components of lease costs, lease term and discount rate with respect of the copier lease with an initial term of more than 12 months are as follows:

 

   Three Months Ended
March 31,
2023
 
Finance lease cost  (unaudited) 
Amortization  $3,189 
Interest on lease liabilities   645 
Total finance lease cost  $3,834 
Weighted Average Remaining Lease Term - Finance leases   3.78 
Weighted Average Discount Rate – Finance leases   5%

 

The following is a schedule, by years, of maturities of finance lease liabilities as of March 31, 2023:

 

For the 12 months ending  Finance
Leases
 
   (unaudited) 
March 31, 2024  $14,890 
March 31, 2025   15,337 
March 31, 2026   11,310 
March 31, 2027   9,967 
March 31, 2028   2,492 
Total undiscounted cash flows   53,996 
Less: imputed interest   (4,900)
Present value of finance lease liabilities  $49,096 

 

13. LOAN PAYABLES

 

In June 2021, the Company entered a loan agreement of $14,549 for purchasing a videojet with interest rate of 14.11% and a term of three-years. In September 2021, the Company entered another loan agreement of $39,218 for purchasing a spectrophotometer workstation with interest rate of 10.26% and a term of five-years. The Company recorded interest expense of $1,091 and $1,345 during the three months ended March 31, 2023 and 2022, respectively.

 

The following is a schedule, by years, of maturities of loan payable as of March31, 2023:

 

For the 12 months ending  Loan Payable 
   (unaudited) 
March 31, 2024  $15,389 
March 31, 2025   10,959 
March 31, 2026   9,974 
March 31, 2027   4,156 
Total undiscounted cash flows   40,478 
Less: imputed interest   (5,932)
Present value of loan payables  $34,546 

 

14. SUBSEQUENT EVENTS

 

The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company did not have any material subsequent event.

 

15

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Business Overview

 

Bio Essence Corporation (“the Company” or “Bio Essence”) was incorporated in 2000 in the state of California. Fusion Diet Systems (“FDS”) was incorporated in 2010 in the state of Utah. Bio Essence and FDS have been owned under common control since 2016. Bio Essence and FDS are mainly engaged in manufacturing and distributing health supplement products. In January 2017, Bio Essence incorporated two subsidiaries in the state of California: BEP and BEH, Bio Essence transferred its manufacturing operation into BEP, and transferred its distributing operation into BEH. On March 1, 2017, the 100% shareholder of FDS transferred all her ownership in FDS into Bio Essence. On December 7, 2021, the Company dissolved FDS. On November 12, 2021, Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in research and development and manufacture of prescription medicine. As a result of the ownership restructure, BEP, BEH, and MCBE became wholly owned subsidiaries of Bio Essence, and Bio Essence serves as a holding corporation for these subsidiaries. McBE has not engaged in any operations since its inception.

 

The primary focus of BEP is producing products for BEH, along with providing OEM services to other companies. BEH targets healthcare practitioners with herbal products in the form of granules, capsules, pills and tablets. It also offers special formulation service to practitioners. The Company intends to develop the subsidiary into an integrated healthcare platform that provides customers direct connections with integrative healthcare practitioners such as dietitians, nutraceutical practitioners, and other practitioners in this discipline worldwide.

 

However, the pandemic could result in significant disruption of global financial markets, reducing the Company’s ability to access capital, which could negatively affect the Company’s liquidity.

 

Related Party Transactions

 

Loans from Officer

 

At March 31, 2023 and December 31, 2022, the Company had loans from one major shareholder (also the Company’s senior officer) of $2,758,766 and $2,543,155, respectively. At March 31, 2023 and December 31, 2022, the Company had loan from another major shareholder for $608,631 for settling the litigation. There are no written loan agreements for these loans. These loans are unsecured, non-interest bearing and have no fixed terms of repayment, and therefore, deemed payable on demand.

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements (“CFS”), which were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported net sales and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are more fully described in Note 2 to our CFS, we believe the following accounting policies are the most critical to assist you in fully understanding and evaluating this management discussion and analysis.

 

Basis of Presentation

 

The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation.

  

The interim consolidated financial information as of March 31, 2023 and for the three-month periods ended March 31 30, 2023 and 2022 was prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures, which are normally included in CFS prepared in accordance with U.S. GAAP were not included. The interim consolidated financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of March 31, 2023, its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022, as applicable, were made. The results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2023 or for any future period.

 

16

 

 

Going Concern

 

The Company incurred net losses of $178,836 and $233,120 for the three months ended March 31, 2023 and 2022, respectively. The Company also had an accumulated deficit of $8,347,431 as of March 31, 2023. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2023 and December 31, 2022, the bad debt allowance was $2,252 and $2,252, respectively.

 

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

 

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.

 

Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the finished goods were delivered to the customers.

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2023 and 2022.

 

17

 

 

Results of operations

 

Comparison of three months ended March 31, 2023 and 2022

 

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales. Certain columns may not add due to rounding.

 

   2023   % of Sales   2022   % of Sales   Dollar
Increase
(Decrease)
   Percent
Increase
(Decrease)
 
Sales of goods  $149,760    43.88%  $181,579    59.26%  $(31,819)   (17.52)%
Manufacture service revenue   191,569    56.12%   124,835    40.74%   66,734    53.46%
Total revenues   341,329    100.00%   306,414    100%   34,915    11.39%
Cost of goods sold   70,500    20.65%   145,665    80.22%   (75,165)   (51.60)%
Cost of manufacture service   104,307    30.56%   90,293    72.33%   14,014    15.52%
Total cost of revenues   174,807    51.21%   235,958    77.01%   (61,151)   (25.92)%
Gross profit   166,522    48.79%   70,456    22.99%   96,066    136.35%
Selling expenses   35,712    10.46%   10,614    3.46%   25,098    236.46%
General and administrative expenses   304,994    89.35%   286,274    93.43%   18,720    6.54%
Operating expenses   340,706    227.50%   296,888    96.89%   43,818    14.76%
Loss from operations   (174,184)   (116.36)%   (226,432)   (73.9)%   52,248    (23.07)%
Other income (expense), net   (4,652)   (1.36)%   (6,688)   (2.18)%   2,036    (30.44)%
Loss before income taxes   (178,836)   (52.39)%   (233,120)   (76.08)%   54,284    (23.29)%
Income tax expense   -    -%   -    -%   -    -%
Net loss  $(178,836)   (52.39)%  $(233,120)   (76.08)%  $54,284    (23.29)%

 

Sales

 

Sales for the three months ended March 31, 2023 and 2022 were $341,329 and $306,414, respectively, an increase of $34,915 or 11.39%. The increase was primarily attributable to (i) increased revenue from manufacture service (OEM) provided by BEP, as we obtained large amount orders from new customers in 2023, offset by (ii) decrease in sales of goods due to lack of stock.

 

Costs of revenue

 

Costs of revenue for the three months ended March 31, 2023 and 2022 was $174,807 and $235,958, respectively, a decrease of $61,151 or 25.92%. The decrease of COGS in 2023 was mainly due to decreased cost of products sold. During the three months ended March 31, 2023, we decreased inventory purchased from overseas so that the freight and shipping cost significantly decreased. In addition, the label cost also decreased in light of the decrease in sales of goods. The percentage of cost of sales of goods to total sales of goods was 47.08% and 80.22% for the three months ended March 31, 2023 and 2022, respectively. The percentage of cost of manufacture services to total manufacture income was 54.45% and 72.33% for the three months ended March 31, 2023 and 2022, respectively.

 

Gross profit

 

For the factors mentioned above, the gross profit for the three months ended March 31, 2023 and 2022 was $166,522 and $70,456, respectively, an increase of $96,066 or 136.35%. The blended profit margin was 48.79% and 23.0% for the three months ended March 31, 2023 and 2022, respectively.

 

Operating expenses

 

Selling expenses consist mainly of advertising, show expense, products marketing, shipping expenses, and promotion expenses. Selling expense was $35,712 for the three months ended March 31, 2023, compared to $10,614 for the three months ended March 31, 2022, an increase of $25,098 or 236.46%, mainly resulting from increased advertising expense by $5,400, increased show expense by $10,510, and increased marketing expense by $9,100.

 

General and administrative expenses consist mainly of employee salaries and welfare, business meeting, utilities, accounting, consulting, and legal expenses. General and administrative expenses were $304,994 for the three months ended March 31, 2023, compared to $286,274 for the three months ended March 31, 2022, an increase of $18,720 or 6.54%, the increase was mainly due to increased salaries expense by $32,370, was partly offset by decreased commission fee by $4,670, and decreased other G&A expenses by $9,080.

 

18

 

 

Other expenses, net

 

Other expenses was $4,652 and $6,688 for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023, other expenses mainly consisted of interest expense of $5,824, financial expense of $976, and net other income of $2,148. For the three months ended March 31, 2022, other expenses mainly consisted of interest expense of $5,160, financial expense of $1,568 and net other income of $40.

 

Net loss

 

We had a net loss of $178,836 for the three months ended March 31, 2023, compared to $233,120 for the three months ended March 31, 2022, a decrease of $54,284 or 23.29%, reflected the above-mentioned factors combined.

 

Liquidity and Capital Resources

 

As of March 31, 2023, we had cash and equivalents of $127, bank overdraft of 70,860, other current assets of $253,648, other current liabilities (excluding bank overdraft) of $3,712,440, working capital deficit of $3,529,525, a current ratio of 0.07:1. As of December 31, 2022, we had cash and equivalents of $6,262, bank overdraft of 53,651, other current assets of $197,569, other current liabilities (excluding bank overdraft) of $3,504,179, working capital deficit of $3,353,999, a current ratio of 0.06:1.The following is a summary of cash provided by or used in each of the indicated types of activities during the three months ended March 31, 2023, and 2022, respectively.

 

   2023   2022 
Net cash used in operating activities  $(231,723)  $(254,475)
Net cash used in investing activities  $-   $- 
Net cash provided by financing activities  $225,588   $254,397 

 

Net cash used in operating activities

 

Net cash used in operating activities was $231,723 for the three months ended March 31, 2023, compared to $254,475 in 2022. The decrease of cash outflow of $22,752 from operating activities for the three months ended March 31, 2023 was principally attributable to decreased net loss by $54,284, decreased cash outflow on accounts receivable by $26,436, and decreased cash outflow on inventory by $53,861, which was partly offset by the increased cash outflow on advance to suppliers by $48,950, increased cash outflow on customer deposit by $29,264, and decreased cash inflow on accrued liabilities and other payable by$23,066.

 

Net cash used in investing activities

 

Net cash used in investing activities was $0 and $0 for the three months ended March 31, 2023 and 2022, respectively.

 

Net cash provided by financing activities

 

Net cash provided by financing activities was $225,588 for the three months ended March 31, 2023, compared to $254,397 in 2022. The net cash provided by financing activities for three months ended March 31, 2023 mainly consisted of proceeds of $215,611 loans from one major shareholder (also the senior officer), decreased bank overdraft of $17,209, but partly offset by repayment of loan payable and finance lease liability of $3,193, and repayment of government loan of $1,071. The net cash provided by financing activities for the three months ended March 31, 2022 consisted of proceeds of $250,000 from loans from one major shareholder (also the senior officer), but partly offset by repayment of loan payable of $3,970.

 

19

 

 

Our current liabilities exceed current assets at March 31, 2023, and we incurred substantial losses and cash outflows from operating activities in the periods presented. We may have difficulty to meet upcoming cash requirements. As of March 31, 2023, our principal source of funds was loans from an officer (also is the Company’s major shareholder). As of March 31, 2022, we believe we will need $1.2 million cash to continue our current business for the next 12 months. In addition to our continuous effort to improve our sales and net profits, we have explored and continue to explore other options to provide additional financing to fund future operations as well as other possible courses of action. Such actions may include, but are not limited to, securing lines of credit, sales of debt or equity securities (which may result in dilution to existing shareholders), loans and cash advances from other third parties or banks, and other similar actions. There can be no assurance that we will be able to obtain additional funding (if needed), on acceptable terms or at all, through a sale of our common stock, loans from financial institutions, or other third parties, or any of the actions discussed above. If we cannot sustain profitable operations, and additional capital is unavailable, lack of liquidity could have a material adverse effect on our business viability, financial position, results of operations and cash flows.

  

Off-Balance Sheet Arrangements

 

We have not entered into any financial guarantees or other commitments to guarantee the obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, as defined in 17 CFR § 229.10(f)(1), we are not required to provide the information requested by this Item.

 

Item 4. Controls and Procedures.

 

The Company’s Chief Executive, Yin Yan, is responsible for establishing and maintaining disclosure controls and procedures for the Company.

 

Evaluation of Disclosure Controls and Procedures

 

For purposes of this Item 4, the term disclosure controls and procedures means controls and other procedures of the Company (i) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (15 U.S.C. 78a et seq. and hereinafter the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and (ii) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

On March 31, 2023, Ms. Yan reviewed the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report and has concluded that the Company’s disclosure controls and procedures are effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC.

 

20

 

 

Report of Management

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”), as defined in Exchange Act Rule 13a-15. Our ICFR is designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. Management conducted an assessment of our ICFR based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on the assessment, management concluded that, as of March 31, 2023, our ICFR were effective at the reasonable assurance level based on those criteria.

 

Our independent public accountant has not conducted an audit of our controls and procedures regarding ICFR and therefore expresses no opinion with regards to the effectiveness or implementation of our controls and procedures with regards to ICFR.

  

Changes in Internal Controls over Financial Reporting

 

There were no changes in our ICFR identified in connection with our evaluation of these controls as of the end of the quarter ending on March 31, 2023 as covered by this report that has materially affected, or is reasonably likely to materially affect, our ICFR.

  

Inherent Limitations on Effectiveness of Controls

 

The Company’s management does not expect that its disclosure controls or its ICFR will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ending on March 31, 2023 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

 

21

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

There have been no unregistered sales of equity securities in the first quarter of 2023.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Not applicable.

 

Item 6. Exhibits.

 

            Incorporated by reference
Exhibit   Exhibit Description   Filed herewith   Form   Period
ending
  Exhibit   Filing
date
31.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   X                
32.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X                
101.INS   Inline XBLR Instance Document                    
101.SCH   Inline XBLR Taxonomy Extension Schema Document                    
101.CAL   Inline XBLR Taxonomy Extension Calculation Linkbase Document                    
101.DEF   Inline XBLR Taxonomy Extension Definition Linkbase Document                    
101.LAB   Inline XBLR Taxonomy Extension Label Linkbase Document                    
101.PRE   Inline EBLR Taxonomy Extension Presentation Linkbase Document                    
104   Cover Page Interactive Data File (formatted as Inline XBLR and Contained in Exhibit 101)                    

 

 

22

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

BIO ESSENCE CORP.

 

/s/ Yin Yan  
By: Yin Yan  
Its: Chairman of the Board, Chief Executive Officer, Chief Financial Officer  
  Date: May 12, 2023  

 

 

23

 

 

 

--12-31 Bio Essence Corp NONE 33009000 33009000 0.01 0.01 9340 2543155 false Q1 0001723059 0001723059 2023-01-01 2023-03-31 0001723059 2023-05-12 0001723059 2023-03-31 0001723059 2022-12-31 0001723059 cik00001723059:SalesOfGoodsMember 2023-01-01 2023-03-31 0001723059 cik00001723059:SalesOfGoodsMember 2022-01-01 2022-03-31 0001723059 cik00001723059:ManufactureServiceRevenueMember 2023-01-01 2023-03-31 0001723059 cik00001723059:ManufactureServiceRevenueMember 2022-01-01 2022-03-31 0001723059 2022-01-01 2022-03-31 0001723059 cik00001723059:CostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723059 cik00001723059:CostOfGoodsSoldMember 2022-01-01 2022-03-31 0001723059 cik00001723059:CostOfManufactureServiceMember 2023-01-01 2023-03-31 0001723059 cik00001723059:CostOfManufactureServiceMember 2022-01-01 2022-03-31 0001723059 us-gaap:CommonStockMember 2022-12-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001723059 us-gaap:RetainedEarningsMember 2022-12-31 0001723059 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001723059 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001723059 us-gaap:CommonStockMember 2023-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001723059 us-gaap:RetainedEarningsMember 2023-03-31 0001723059 us-gaap:CommonStockMember 2021-12-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001723059 us-gaap:RetainedEarningsMember 2021-12-31 0001723059 2021-12-31 0001723059 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001723059 us-gaap:CommonStockMember 2022-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001723059 us-gaap:RetainedEarningsMember 2022-03-31 0001723059 2022-03-31 0001723059 cik00001723059:OwnershipMember 2017-03-01 0001723059 cik00001723059:GoingConcernMember 2023-03-31 0001723059 cik00001723059:OneMajorCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001723059 cik00001723059:OneMajorCustomerMember 2023-01-01 2023-03-31 0001723059 cik00001723059:OneVendorMember 2023-01-01 2023-03-31 0001723059 cik00001723059:TwoVendorMember 2023-01-01 2023-03-31 0001723059 cik00001723059:ThreeVendorsMember 2023-01-01 2023-03-31 0001723059 cik00001723059:OneVendorMember 2022-01-01 2022-03-31 0001723059 cik00001723059:TwoVendorMember 2022-01-01 2022-03-31 0001723059 cik00001723059:ThreeVendorsMember 2022-01-01 2022-03-31 0001723059 cik00001723059:FourVendorMember 2022-01-01 2022-03-31 0001723059 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2023-03-31 0001723059 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2023-03-31 0001723059 us-gaap:OfficeEquipmentMember 2023-03-31 0001723059 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001723059 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001723059 us-gaap:OfficeEquipmentMember 2022-12-31 0001723059 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-03-31 0001723059 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-12-31 0001723059 us-gaap:TrademarksMember 2023-03-31 0001723059 us-gaap:TrademarksMember 2022-12-31 0001723059 cik00001723059:PPPLoanMember 2023-03-31 0001723059 cik00001723059:PPPLoanMember 2023-01-01 2023-03-31 0001723059 2021-02-01 2021-02-28 0001723059 2021-01-01 2021-12-31 0001723059 cik00001723059:EconomicInjuryDisasterLoanMember 2023-01-01 2023-03-31 0001723059 cik00001723059:SeniorOfficerMember 2023-01-01 2023-03-31 0001723059 cik00001723059:SeniorOfficerMember 2022-01-01 2022-12-31 0001723059 cik00001723059:Shareholder1Member 2023-03-31 0001723059 2022-01-01 2022-12-31 0001723059 2019-01-01 2019-03-31 0001723059 2020-01-01 2020-03-31 0001723059 2021-01-01 2021-03-31 0001723059 cik00001723059:FederalAndCaliforniaMember 2023-03-31 0001723059 cik00001723059:FederalAndCaliforniaMember 2022-12-31 0001723059 2018-10-01 0001723059 2018-10-01 2018-10-01 0001723059 cik00001723059:LeasesOneMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesTwoMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesThreeMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesFourMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesThreeMember 2022-03-01 2022-03-15 0001723059 cik00001723059:LeasesFourMember 2022-03-01 2022-03-15 0001723059 cik00001723059:LeaseFiveMember 2022-03-01 2022-06-24 0001723059 cik00001723059:LeaseSixMember 2022-03-01 2022-06-24 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2023-01-01 2023-03-31 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2022-01-01 2022-03-31 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2023-03-31 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2022-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2023-01-01 2023-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2022-01-01 2022-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2023-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2022-03-31 0001723059 cik00001723059:OperatingLeasesMember 2023-03-31 0001723059 cik00001723059:OperatingLeasesMember 2023-01-01 2023-03-31 0001723059 cik00001723059:FinanceLeaseMember 2023-03-31 0001723059 cik00001723059:FinanceLeaseMember 2023-01-01 2023-03-31 0001723059 2021-06-30 0001723059 2021-09-30 0001723059 cik00001723059:OperatingLeaseMember 2023-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0323ex31-1_bioessence.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES AND EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.

 

BIO ESSENCE CORP.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

 

I, Yin Yan, certify that:

 

1. I have reviewed this Form 10-Q of Bio Essence Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am the registrant’s principal executive officer and thus am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, including but not limited to those identified in Item 4 (Controls and Procedures) in the registrant’s quarterly report on Form 10-Q; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: May 12, 2023

 

By: /s/ Yin Yan  
  Yin Yan  
  Chief Executive Officer  
  (Principal Executive Officer)  

 

EX-31.2 3 f10q0323ex31-2_bioessence.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES AND EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.

 

BIO ESSENCE CORP.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

 

I, Yin Yan, certify that:

 

1. I have reviewed this Form 10-Q of Bio Essence Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am the registrant’s principal financial officer and am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information in the registrant’s quarterly report on Form 10-Q; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: May 12, 2023

 

By: /s/ Yin Yan  
  Yin Yan  
  Chief Financial Officer  
  (Principal Financial Officer)  

 

EX-32.1 4 f10q0323ex32-1_bioessence.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES AND EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.

 

CERTIFICATE OF CHIEF EXECUTIVE OFFICER

 

BIO ESSENCE CORP.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Bio Essence Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yin Yan, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to Yin Yan and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: May 12, 2023

 

By: /s/ Yin Yan  
  Yin Yan  
  Chief Executive Officer  
  (Principal Executive Officer)  

 

EX-32.2 5 f10q0323ex32-2_bioessence.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES AND EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.

 

CERTIFICATE OF CHIEF FINANCIAL OFFICER

 

BIO ESSENCE CORP.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report for Bio Essence Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yin Yan, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

(3)A signed original of this written statement required by Section 906 has been provided to Yin Yan and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: May 12, 2023

 

By: /s/ Yin Yan  
  Yin Yan  
  Chief Financial Officer  
  (Principal Financial Officer)  

 

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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cik00001723059-20230331.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Stockholders’ Deficit (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Security Deposit link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Intangible Assets, Net link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Taxes Payable link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Accrued Liabilities and Other Payables link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Government Loans Payable link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Loan Payables link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Accrued Liabilities and Other Payables (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Government Loans Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Loan Payables (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Inventory (Details) - Schedule of inventory link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Security Deposit (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Intangible Assets, Net (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible assets link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Taxes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Government Loans Payable (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Government Loans Payable (Details) - Schedule of future minimum loan payments link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Income Taxes (Details) - Schedule of federal statutory income tax rate and the effective income tax link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Income Taxes (Details) - Schedule of income tax expense link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Leases (Details) - Schedule of lease costs, lease term and discount rate link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Leases (Details) - Schedule of lease liabilities link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Loan Payables (Details) link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Loan Payables (Details) - Schedule of maturities of loan payable link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 cik00001723059-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cik00001723059-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cik00001723059-20230331_lab.xml XBRL LABEL FILE EX-101.PRE 11 cik00001723059-20230331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2023
May 12, 2023
Document Information Line Items    
Entity Registrant Name Bio Essence Corp  
Trading Symbol N/A  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   33,009,000
Amendment Flag false  
Entity Central Index Key 0001723059  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Mar. 31, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period true  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 333-232839  
Entity Incorporation, State or Country Code CA  
Entity Tax Identification Number 94-3349551  
Entity Address, Address Line One 8 Studebaker  
Entity Address, Address Line Two Drive in  
Entity Address, City or Town Irvine  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92618  
City Area Code (949)  
Local Phone Number 706-9966  
Entity Interactive Data Current Yes  
Title of 12(b) Security N/A  
Security Exchange Name NONE  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash and equivalents $ 127 $ 6,262
Accounts receivable, net 10,700 5,599
Prepaid expenses 8,630 8,820
Advance to suppliers 61,573 1,987
Inventory, net (Note 3) 172,745 181,163
Total current assets 253,775 203,831
NONCURRENT ASSETS    
Security deposit (Note 4) 41,841 41,841
Right-of-use assets, net 1,015,457 1,054,872
Property and equipment, net (Note 5) 230,036 246,379
Intangible assets, net (Note 6) 744 802
Total non-current assets 1,288,078 1,343,894
TOTAL ASSETS 1,541,853 1,547,725
CURRENT LIABILITIES    
Bank overdraft 70,860 53,651
Accounts payable 58,334 49,776
Taxes payable (Note 7) 12,899 8,392
Accrued liabilities and other payables (Note 8) 67,118 91,645
Accrued interest on government loans 16,805 16,867
Operating lease liabilities (Note 12) 160,176 156,560
Finance lease liabilities (Note 12) 12,761 12,603
Loan payables (Note 13) 12,311 11,954
Government loans payable - current portion (Note 9) 4,639 4,596
Loan from shareholder (Note 10) 3,367,397 3,151,786
Total current liabilities 3,783,300 3,557,830
NONCURRENT LIABILITIES    
Operating lease liabilities (Note 12) 908,040 952,756
Finance lease liabilities (Note 12) 36,335 39,687
Loan payables (Note 13) 22,236 25,561
Government loans payable (Note 9) 209,193 210,306
Total non-current liabilities 1,175,804 1,228,310
TOTAL LIABILITIES 4,959,104 4,786,140
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT    
Preferred stock $0.0001 par value; authorized shares 10,000,000
Common stock $0.0001 par value; authorized shares 100,000,000; issued and outstanding shares 33,009,000 as of March 31, 2023 and December 31, 2022 3,301 3,301
Additional paid in capital 4,926,879 4,926,879
Accumulated deficit (8,347,431) (8,168,595)
TOTAL STOCKHOLDERS’ DEFICIT (3,417,251) (3,238,415)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,541,853 $ 1,547,725
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 33,009,000 33,009,000
Common stock, shares outstanding 33,009,000 33,009,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues    
Total revenues $ 341,329 $ 306,414
Cost of revenues    
Total cost of revenues 174,807 235,958
Gross profit 166,522 70,456
Operating expenses    
Selling 35,712 10,614
General and administrative 304,994 286,274
Total operating expenses 340,706 296,888
Loss from operations (174,184) (226,432)
Other income (expenses)    
Interest expense (5,824) (5,160)
Financial expense (976) (1,568)
Other income 2,497 535
Other expense (349) (495)
Other expenses, net (4,652) (6,688)
Loss before income tax (178,836) (233,120)
Income tax expense
Net loss $ (178,836) $ (233,120)
Basic and diluted weighted average shares outstanding (in Shares) 33,009,000 33,009,000
Basic and diluted net loss per share (in Dollars per share) $ (0.01) $ (0.01)
Sales of goods    
Revenues    
Total revenues $ 149,760 $ 181,579
Manufacture service revenue    
Revenues    
Total revenues 191,569 124,835
Cost of goods sold    
Cost of revenues    
Total cost of revenues 70,500 145,665
Cost of manufacture service    
Cost of revenues    
Total cost of revenues $ 104,307 $ 90,293
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Weighted average shares outstanding, diluted 33,009,000 33,009,000
Net loss per share, diluted $ (0.01) $ (0.01)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders’ Deficit (Unaudited) - USD ($)
COMMON - STOCK
ADDITIONAL PAID IN CAPITAL
ACCUMULATED DEFICIT
Total
Balance at Dec. 31, 2021 $ 3,301 $ 4,926,879 $ (7,358,916) $ (2,428,736)
Balance (in Shares) at Dec. 31, 2021 33,009,000      
Net loss     (233,120) (233,120)
Balance at Mar. 31, 2022 $ 3,301 4,926,879 (7,592,036) (2,661,856)
Balance (in Shares) at Mar. 31, 2022 33,009,000      
Balance at Dec. 31, 2022 $ 3,301 4,926,879 (8,168,595) (3,238,415)
Balance (in Shares) at Dec. 31, 2022 33,009,000      
Net loss (178,836) (178,836)
Balance at Mar. 31, 2023 $ 3,301 $ 4,926,879 $ (8,347,431) $ (3,417,251)
Balance (in Shares) at Mar. 31, 2023 33,009,000      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (178,836) $ (233,120)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 16,401 10,874
Operating lease expense 53,110 57,717
Increase (decrease) in assets: Changes in assets / liabilities:    
Accounts receivable (5,103) (31,539)
Prepaid expenses 190 (5,536)
Advance to suppliers (59,586) (10,636)
Inventory 8,419 (45,442)
Accounts payable 8,558 28,291
Customer deposit (29,264)
Accrued liabilities and other payables 4,738 27,804
Accrued interest (62)
Taxes payable 4,507 4,319
Payment on lease liabilities (54,795) (57,207)
Net cash used in operating activities (231,723) (254,475)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Bank overdraft 17,209 8,367
Repayment of finance lease liabilities (3,193)
Repayment of government loans (1,071)
Repayment of loan payables (2,968) (3,970)
Loan from shareholder 215,611 250,000
Net cash provided by financing activities 225,588 254,397
NET DECREASE IN CASH & EQUIVALENTS (6,135) (78)
CASH & EQUIVALENTS, BEGINNING OF PERIOD 6,262 303
CASH & EQUIVALENTS, END OF PERIOD 127 225
Supplemental Cash Flow Data:    
Income tax paid
Interest paid 5,883 6,098
Supplemental disclosures of non-cash financing activities:    
Fixed assets obtained in exchange for new finance lease liabilities $ 16,077
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Description of Business
3 Months Ended
Mar. 31, 2023
Organization and Description of Business [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Bio Essence Corporation (“the Company” or “Bio Essence”) was incorporated in 2000 in the state of California. Fusion Diet Systems (“FDS”) was incorporated in 2010 in the state of Utah. Bio Essence and FDS were under common control since 2016. Bio Essence and FDS are mainly engaged in manufacturing and distributing health supplement products. In January 2017, Bio Essence incorporated two subsidiaries in the state of California: Bio Essence Pharmaceutical Inc. (“BEP”) and Bio Essence Herbal Essentials, Inc. (“BEH”), Bio Essence transferred its manufacturing operation to BEP, and transferred its distributing operation to BEH. On March 1, 2017, the 100% shareholder of FDS transferred all of her ownership in FDS to Bio Essence. On December 7, 2021, the Company dissolved FDS. On November 12, 2021, Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in developing, manufacturing and sales of prescription medicine. As a result of the ownership restructure, BEP BEH and McBE became wholly owned subsidiaries of Bio Essence. McBE has not engaged any operations since its inception.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Consolidation

 

The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation.

 

The interim consolidated financial information as of March 31, 2023 and for the three-month periods ended March 31 30, 2023 and 2022 was prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures, which are normally included in CFS prepared in accordance with U.S. GAAP were not included. The interim consolidated financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of March 31, 2023, its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022, as applicable, were made. The results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2023 or for any future period.

 

Reclassification

 

Certain prior period accounts have been reclassified in conformity with current period’s presentation. These reclassifications had no impact on the reported results of operations and cash flows.

 

Going Concern

 

The Company incurred net losses of $178,836 and $233,120 for the three months ended March 31, 2023 and 2022, respectively. The Company also had an accumulated deficit of $8,347,431 as of March 31, 2023. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Leases

 

The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s consolidated balance sheets.

 

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

The Company elected the package of practical expedients permitted under the transition guidance to combine the lease and non-lease components as a single lease component for operating leases associated with the Company’s office space lease, and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.

 

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. The Company recognized no impairment of ROU assets as of March 31, 2023 and December 31, 2022.

 

Cash and Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2023 and December 31, 2022, the bad debt allowance was $2,252 and $2,252, respectively.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value with cost determined on a weighted-average basis. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down their inventories to net realizable value, if lower.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets as follows:

 

Leasehold improvements   7-10 years
Office furniture   5  years

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

 

Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of March 31, 2023 and December 31, 2022, there was no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets also include the prior years’ net operating losses carried forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

At March 31, 2023 and December 31, 2022, the Company did not take any uncertain positions that would necessitate recording a tax related liability. The Company files a U.S. income tax return. With few exceptions, the Company’s U.S. income tax return filed for the years ending on December 31, 2019 and thereafter are subject to examination by the relevant taxing authorities.


The Company accounts for income taxes in interim periods in accordance with FASB ASC 740-270, “Interim Reporting.” The Company has determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during the Company’s fiscal year to its best current estimate. The estimated annual effective tax rate is applied to the year-to-date ordinary income (or loss) at the end of the interim period.

 

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

 

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.

 

Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the manufactured goods were delivered to the customers.

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2023 and 2022.

 

Cost of Revenue

 

Cost of goods sold (“COGS”) consists primarily of finished goods purchased from other manufacturers, material costs, labor costs and related overhead that are directly attributable to the production of the products. Write-down of inventory to lower of cost or net realizable value is also recorded in COGS.

 

Cost of manufacture service consists primarily of direct labor costs and related overhead that are directly attributable to the manufacture process.

 

Shipping and Handling Costs

 

Shipping and handling costs related to delivery of finished goods are included in selling expenses. During the three months ended March 31, 2023 and 2022, shipping and handling costs were $9,416 and $9,340, respectively.

 

Advertising

 

Advertising expenses consist primarily of costs of promotion and marketing for the Company’s image and products, and costs of direct advertising, and are included in selling expenses. The Company expenses all advertising costs as incurred. During the three months ended March 31, 2023 and 2022, advertising expense was $5,400 and $1,274, respectively.

 

Fair Value (“FV”) of Financial Instruments

 

Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:

 

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.

 

As of March 31, 2023 and December 31, 2022, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV. The carrying value of cash, accounts receivable, prepaid expenses, advances to suppliers, accounts payable, taxes payable, other payables and accrued liabilities approximate estimated fair values because of their short maturities.

 

Share-based Compensation

 

The Company accounts for share-based compensation awards in accordance with ASC 718, “Compensation – Stock Compensation”. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date and amortized on a straight-line basis over the requisite service period or vesting period. The Company records forfeitures as they occur.

 

Earnings (Loss) per Share (EPS)

 

Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed similar to basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if all the potential common shares pertaining to warrants, stock options, and similar instruments had been issued and if the additional common shares were dilutive. Diluted EPS are based on the assumption that all dilutive convertible shares and stock options and warrants were converted or exercised. Dilution is computed by applying the treasury stock method for the outstanding unvested restricted stock, options and warrants, and the if-converted method for the outstanding convertible instruments. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later) and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, outstanding convertible instruments are assumed to be converted into common stock at the beginning of the period (or at the time of issuance, if later). There were no potentially dilutive securities outstanding (options and warrants) for the three months ended March 31, 2023 and 2022.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.

 

For the three months ended March 31, 2023, the company had one major customer accounted for 34% of the Company’s total sales. For the three months ended March 31, 2022, the company had one major customer accounted for 27% of the Company’s total sales.

 

The Company had three major vendors accounted for 22%, 20%, and 17% respectively, of total purchases during the three months ended March 31, 2023. The Company had four major vendors accounted for 23%, 19%, 10% and 10%, respectively, of total purchases during the three months ended March 31, 2022.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: manufacture and sale of health supplement products.

 

New Accounting Pronouncements

 

Recently issued accounting pronouncements not yet adopted

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company is currently evaluating the impact that ASU 2020-06 may have on its CFS and related disclosures.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory
3 Months Ended
Mar. 31, 2023
Inventory [Abstract]  
INVENTORY

3. INVENTORY

 

Inventory consisted of the following at March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Raw materials  $57,438   $60,705 
Finished goods – health supplements   141,425    146,576 
Less: inventory impairment allowance   (26,118)   (26,118)
Total  $172,745   $181,163 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Security Deposit
3 Months Ended
Mar. 31, 2023
Security Deposit [Abstract]  
SECURITY DEPOSIT

4. SECURITY DEPOSIT

 

As of March 31, 2023 and December 31, 2022, the security deposit was for rent of the Company’s office and warehouse of $41,841.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, Net
3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

5. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Leaseholder improvements  $57,067   $57,067 
Office furniture and equipment   406,241    406,241 
Total   463,308    463,308 
Less: accumulated depreciation   (233,272)   (216,929)
Net  $230,036   $246,379 

 

Depreciation for the three months ended March 31, 2023 and 2022 was $16,342 and $10,815, respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets, Net
3 Months Ended
Mar. 31, 2023
Intangible Assets, Net [Abstract]  
INTANGIBLE ASSETS, NET

6. INTANGIBLE ASSETS, NET

 

Intangible assets consisted of the following as of March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Computer Software  $36,928   $36,928 
Trademark   2,350    2,350 
Total   39,278    39,278 
Less: accumulated amortization   (38,534)   (38,476)
Net  $744   $802 

 

Amortization of intangible assets was $59 and $6,349 for the three months ended March 31, 2023 and 2022, respectively.

 

Estimated amortization for the existing intangible assets with finite lives for each of the next five years at March 31, 2023 is as follows: $235, $235, $235 and $39.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Taxes Payable
3 Months Ended
Mar. 31, 2023
Tax Payable [Abstract]  
TAXES PAYABLE

7. TAXES PAYABLE

 

Taxes payable at March 31 2023, and December 31, 2022, was for sales tax and payroll tax payable of $12,899 and $8,392, respectively.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities and Other Payables
3 Months Ended
Mar. 31, 2023
Accrued Liabilities and Other Payables [Abstract]  
ACCRUED LIABILITIES AND OTHER PAYABLES

8. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following March 31, 2023 and December 31, 2022:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Accrued expenses  $6,810   $6,756 
Credit card payable   43,960    39,277 
Customer deposit   16,348    45,612 
           
Total  $67,118   $91,645 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Government Loans Payable
3 Months Ended
Mar. 31, 2023
Government Loans Payable [Abstract]  
GOVERNMENT LOANS PAYABLE

9. GOVERNMENT LOANS PAYABLE

 

In May and June 2020, BEH, BEP and FDS received a total of $127,740 from the Paycheck Protection Program loan (“PPP loan”) from US Small Business Administration (“the SBA”). The loan will be fully forgiven if the funds are used for payroll costs, interest on mortgages, rent, and utilities (at least 60% of the forgiven amount must have been used for payroll). The loan amount not forgiven, will have annual interest of 1%. Loan payments will be deferred to either (1) the date that SBA remits the borrower’s loan forgiveness amount to the lender or (2) if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness covered period. Loans issued prior to June 5, 2020 have a maturity of two years, loans issued after June 5, 2020 have a maturity of five years. No collateral or personal guarantees are required. A borrower may apply for loan forgiveness any time on or before the maturity date of the loan, including before the end of the Covered Period (either (1) the 24-week (168-day) period beginning on the PPP Loan Disbursement Date, or (2) if the Borrower received its PPP loan before June 5, 2020, the Borrower may elect to use an eight-week (56-day) Covered Period); provided such application for loan forgiveness is made within 10 months after the last day of the covered period, otherwise the loan is no longer deferred and the borrower must begin paying principal and interest. Subsequently, The U.S. Treasury and SBA announced a streamlined PPP forgiveness application for loans of $50,000 or less (unless those borrowers together with their affiliates received loans totaling $2 million or more). It requires fewer calculations and may call for less documentation. It does not require borrowers to reduce their loan forgiveness calculations if they have reduced full-time equivalent (“FTE”) or salaries. In addition, in February 2021, BEH, BEP and FDS received a total of $115,245 from the second round of PPP loan from the SBA. As of December 31, 2021, all BEH, BEP and FDS’ PPP loans’ forgiveness were approved and the Company recorded $242,985 PPP loan forgiveness as other income in the year ended December 31, 2021.

 

In May and June 2020, BEH, BEP and FDS received total of $215,600 from the Economic Injury Disaster Loan (“EIDL loan”) from the SBA after deducting $100 Uniform Commercial Code (“UCC”) handling charge and filing fee for each company. This is a low-interest federal disaster loan for working capital to small businesses and non-profit organizations of any size suffering substantial economic injury as a result of the Coronavirus (COVID-19), to help the businesses to meet financial obligations and operating expenses that could have been met had the disaster not occurred. This loan has interest of 3.75% and is not forgivable. The maturity of the loan is 30 years, installment payments including principal and interest of $515 monthly will begin 12 months from the date of the promissory note. On March 4, 2022, The FDS transferred its EIDL loan to BEC due to the dissolution of FDS. The SBA extended the deferment period to allow small businesses and not-for-profits that received EIDL funds do not have to begin payments on the loan until 30 months after the date of the note. Accordingly, the company began to make installment payments in the fourth quarter 2022.

 

As of March 31, 2023, the future minimum EIDL loan payments to be paid by year are as follows:

 

Year Ending  Amount 
   (unaudited) 
     
March 31, 2024  $4,639 
March 31, 2025   4,816 
March 31, 2026   5,000 
March 31, 2027   5,191 
March 31, 2028   5,389 
Thereafter   188,797 
Total  $213,832 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

10. RELATED PARTY TRANSACTIONS

 

Loans from Shareholder

 

At March 31, 2023 and December 31, 2022, the Company had loans from one major shareholder (also the Company’s senior officer) for $2,758,766 and $2,543155, respectively. At March 31, 2023 and December, 2022, the Company had loan from another major shareholder for $608,631 for settling the litigation. There are no written loan agreements for these loans. These loans are unsecured, non-interest bearing and have no fixed terms of repayment, and therefore, deemed payable on demand. Cash flows from loans form shareholder are classified as cash flows from financing activities.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES

11. INCOME TAXES

 

The Company and its subsidiaries are subject to 21% federal corporate income tax in US.

 

At March 31, 2023 and December, 2022, the Company had net operating loss (“NOL”) for income tax purposes; for federal income tax purposes, the NOL arising in tax years beginning after 2017 may only reduce 80% of a taxpayer’s taxable income, and may be carried forward indefinitely; for California income tax purposes, the entire NOL can be carried forward up to 20 years. However, the coronavirus Aid, Relief and Economic Security Act (“the CARES Act”) issued in March 2020, provides tax relief to both corporate and noncorporate taxpayers by adding a five-year carryback period and temporarily repealing the 80% limitation for NOLs arising in 2019, 2020 and 2021.

 

The Company has NOL carry-forwards for Federal and California income tax purposes of $5.42 million and $5.25 million at March 31, 2023 and December 31, 2022, respectively. No tax benefit was reported with respect to these NOL carry-forwards in the accompanying consolidated financial statements because the Company believes the realization of the Company’s net deferred tax assets for the NOL for both federal and California State of approximately $1.52 million as of March 31, 2023, was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are fully offset by a full valuation allowance.

 

Components of the Company’s deferred tax assets as of March 31, 2023 and December 31, 2022 are as follows:

 

   March 31,
2023
   December 31,
2022
 
   (unaudited)     
Net deferred tax assets:        
Bad debt expense  $1,978   $1,978 
Inventory impairment   697    697 
Operating lease charge   13,596    14,020 
Depreciation and amortization   237    237 
Expected income tax benefit from NOL carry-forwards   1,517,801    1,467,801 
Less: valuation allowance   (1,534,309)   (1,484,733)
Deferred tax assets, net of valuation allowance  $
-
   $
-
 

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the consolidated federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes for the three months ended March 31, 2023 and 2022 is as follows:

 

   2023   2022 
   (unaudited)   (unaudited) 
Federal statutory income tax expense (benefit) rate   (21.00)%   (21.00)%
State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax   (6.98)%   (6.98)%
Change in valuation allowance   27.98%   27.98%
Effective income tax rate   
-
%   
-
%

 

The provision for income tax expense for the three months ended March 31, 2023 and 2022 consisted of the following:

 

   2023   2022 
   (unaudited)   (unaudited) 
Income tax expense – current  $
-
   $
-
 
Income tax benefit – current   
-
    
-
 
Total income tax expense  $
        
   $
       
 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
LEASES

12. LEASES

 

Operating Leases

 

Warehouse and office lease

 

Effective October 1, 2018, the Company entered a 62.5 months lease for a facility including warehouse and office in the City of Irvine, California, with a security deposit of $41,841. The monthly rent is approximately $16,200 with a 3% increase each year. The lease provided an option to extend at lease maturity for another five-years, with six months prior written notice of lessee’s intention to extend the lease. The Company’s CEO is the guarantor of this lease. Lessor will have the right to proceed against guarantor following any breach or default by lessee without first proceeding against lessee and without previous notice to or demand upon either lessee or guarantor.

 

The components of lease costs, lease term and discount rate with respect of warehouse and office lease in the City of Irvine with an initial term of more than 12 months are as follows:

 

   Three Months Ended
March 31,
2023
   Three Months Ended
March 31,
2022
 
   (unaudited)   (unaudited) 
Operating lease cost  $53,281   $53,281 
Weighted Average Remaining Lease Term - Operating leases including options to renew   5.51 years    6.51 years 
Weighted Average Discount Rate - Operating leases   5%   5%

 

The following is a schedule, by years, of maturities of warehouse and office lease liabilities as of March 31, 2023:

 

For the 12 months ending  Operating
Leases
 
   (unaudited) 
March 31, 2024  $205,848 
March 31, 2025   225,757 
March 31, 2026   225,757 
March 31, 2027   225,757 
March 31, 2028   225,757 
Thereafter   112,876 
Total undiscounted cash flows   1,221,752 
Less: imputed interest   (153,535)
Present value of lease liabilities  $1,068,217 

 

Equipment leases

 

In 2017, the Company entered two leases for two copiers with terms of 60 and 63 months respectively, and monthly payments of $162 and $213, respectively. The Company also entered two leases for two forklifts with a term of 60 months for each, and the monthly payment was $292 and $669, respectively. All these equipment lease expired in 2022.

 

The components of lease costs, lease term and discount rate with respect of these equipment leases are as follows:

 

   Three Months Ended
March 31,
2023
   Three Months Ended
March 31,
2022
 
   (unaudited)   (unaudited) 
Operating lease cost  $0.00   $4,008 
Weighted Average Remaining Lease Term - Operating leases   0.00 years    0.19 years 
Weighted Average Discount Rate - Operating leases   5%   5%

 

Finance lease

 

Effective March 15, 2022, the company entered two 39-months lease for two copiers with same vendor for a monthly payment of $234 and $214, respectively. Effective June 24, 2022, the company entered two leases for two forklifts with a term of 60 months for each, and the monthly payment was $383 and $451, respectively. At the lease expiration date, the Company has the option to purchase the copier for $1 each.

 

The components of lease costs, lease term and discount rate with respect of the copier lease with an initial term of more than 12 months are as follows:

 

   Three Months Ended
March 31,
2023
 
Finance lease cost  (unaudited) 
Amortization  $3,189 
Interest on lease liabilities   645 
Total finance lease cost  $3,834 
Weighted Average Remaining Lease Term - Finance leases   3.78 
Weighted Average Discount Rate – Finance leases   5%

 

The following is a schedule, by years, of maturities of finance lease liabilities as of March 31, 2023:

 

For the 12 months ending  Finance
Leases
 
   (unaudited) 
March 31, 2024  $14,890 
March 31, 2025   15,337 
March 31, 2026   11,310 
March 31, 2027   9,967 
March 31, 2028   2,492 
Total undiscounted cash flows   53,996 
Less: imputed interest   (4,900)
Present value of finance lease liabilities  $49,096 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Loan Payables
3 Months Ended
Mar. 31, 2023
Loan Payables [Abstract]  
LOAN PAYABLES

13. LOAN PAYABLES

 

In June 2021, the Company entered a loan agreement of $14,549 for purchasing a videojet with interest rate of 14.11% and a term of three-years. In September 2021, the Company entered another loan agreement of $39,218 for purchasing a spectrophotometer workstation with interest rate of 10.26% and a term of five-years. The Company recorded interest expense of $1,091 and $1,345 during the three months ended March 31, 2023 and 2022, respectively.

 

The following is a schedule, by years, of maturities of loan payable as of March31, 2023:

 

For the 12 months ending  Loan Payable 
   (unaudited) 
March 31, 2024  $15,389 
March 31, 2025   10,959 
March 31, 2026   9,974 
March 31, 2027   4,156 
Total undiscounted cash flows   40,478 
Less: imputed interest   (5,932)
Present value of loan payables  $34,546 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

14. SUBSEQUENT EVENTS

 

The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company did not have any material subsequent event.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Accounting Policies, by Policy (Policies)
3 Months Ended
Mar. 31, 2023
Organization and Description of Business [Abstract]  
Basis of Presentation and Consolidation

Basis of Presentation and Consolidation

 

The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation.

 

The interim consolidated financial information as of March 31, 2023 and for the three-month periods ended March 31 30, 2023 and 2022 was prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures, which are normally included in CFS prepared in accordance with U.S. GAAP were not included. The interim consolidated financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of March 31, 2023, its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022, as applicable, were made. The results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2023 or for any future period.

 

Reclassification

Reclassification

 

Certain prior period accounts have been reclassified in conformity with current period’s presentation. These reclassifications had no impact on the reported results of operations and cash flows.

 

Going Concern

Going Concern

 

The Company incurred net losses of $178,836 and $233,120 for the three months ended March 31, 2023 and 2022, respectively. The Company also had an accumulated deficit of $8,347,431 as of March 31, 2023. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Leases

Leases

 

The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s consolidated balance sheets.

 

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

The Company elected the package of practical expedients permitted under the transition guidance to combine the lease and non-lease components as a single lease component for operating leases associated with the Company’s office space lease, and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.

 

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. The Company recognized no impairment of ROU assets as of March 31, 2023 and December 31, 2022.

 

Cash and Equivalents

Cash and Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Accounts Receivable

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2023 and December 31, 2022, the bad debt allowance was $2,252 and $2,252, respectively.

 

Inventory

Inventory

 

Inventories are stated at the lower of cost or net realizable value with cost determined on a weighted-average basis. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down their inventories to net realizable value, if lower.

 

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets as follows:

 

Leasehold improvements   7-10 years
Office furniture   5  years

 

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

 

Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of March 31, 2023 and December 31, 2022, there was no significant impairments of its long-lived assets.

 

Income Taxes

Income Taxes

 

Income taxes are accounted for using an asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets also include the prior years’ net operating losses carried forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

At March 31, 2023 and December 31, 2022, the Company did not take any uncertain positions that would necessitate recording a tax related liability. The Company files a U.S. income tax return. With few exceptions, the Company’s U.S. income tax return filed for the years ending on December 31, 2019 and thereafter are subject to examination by the relevant taxing authorities.


The Company accounts for income taxes in interim periods in accordance with FASB ASC 740-270, “Interim Reporting.” The Company has determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during the Company’s fiscal year to its best current estimate. The estimated annual effective tax rate is applied to the year-to-date ordinary income (or loss) at the end of the interim period.

 

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

 

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.

 

Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the manufactured goods were delivered to the customers.

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2023 and 2022.

 

Cost of Revenue

Cost of Revenue

 

Cost of goods sold (“COGS”) consists primarily of finished goods purchased from other manufacturers, material costs, labor costs and related overhead that are directly attributable to the production of the products. Write-down of inventory to lower of cost or net realizable value is also recorded in COGS.

 

Cost of manufacture service consists primarily of direct labor costs and related overhead that are directly attributable to the manufacture process.

 

Shipping and Handling Costs

Shipping and Handling Costs

 

Shipping and handling costs related to delivery of finished goods are included in selling expenses. During the three months ended March 31, 2023 and 2022, shipping and handling costs were $9,416 and $9,340, respectively.

 

Advertising

Advertising

 

Advertising expenses consist primarily of costs of promotion and marketing for the Company’s image and products, and costs of direct advertising, and are included in selling expenses. The Company expenses all advertising costs as incurred. During the three months ended March 31, 2023 and 2022, advertising expense was $5,400 and $1,274, respectively.

 

Fair Value (“FV”) of Financial Instruments

Fair Value (“FV”) of Financial Instruments

 

Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

Fair Value Measurements and Disclosures

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:

 

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.

 

As of March 31, 2023 and December 31, 2022, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV. The carrying value of cash, accounts receivable, prepaid expenses, advances to suppliers, accounts payable, taxes payable, other payables and accrued liabilities approximate estimated fair values because of their short maturities.

 

Share-based Compensation

Share-based Compensation

 

The Company accounts for share-based compensation awards in accordance with ASC 718, “Compensation – Stock Compensation”. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date and amortized on a straight-line basis over the requisite service period or vesting period. The Company records forfeitures as they occur.

 

Earnings (Loss) per Share (EPS)

Earnings (Loss) per Share (EPS)

 

Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed similar to basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if all the potential common shares pertaining to warrants, stock options, and similar instruments had been issued and if the additional common shares were dilutive. Diluted EPS are based on the assumption that all dilutive convertible shares and stock options and warrants were converted or exercised. Dilution is computed by applying the treasury stock method for the outstanding unvested restricted stock, options and warrants, and the if-converted method for the outstanding convertible instruments. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later) and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, outstanding convertible instruments are assumed to be converted into common stock at the beginning of the period (or at the time of issuance, if later). There were no potentially dilutive securities outstanding (options and warrants) for the three months ended March 31, 2023 and 2022.

 

Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.

 

For the three months ended March 31, 2023, the company had one major customer accounted for 34% of the Company’s total sales. For the three months ended March 31, 2022, the company had one major customer accounted for 27% of the Company’s total sales.

 

The Company had three major vendors accounted for 22%, 20%, and 17% respectively, of total purchases during the three months ended March 31, 2023. The Company had four major vendors accounted for 23%, 19%, 10% and 10%, respectively, of total purchases during the three months ended March 31, 2022.

 

Segment Reporting

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: manufacture and sale of health supplement products.

 

New Accounting Pronouncements

New Accounting Pronouncements

 

Recently issued accounting pronouncements not yet adopted

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company is currently evaluating the impact that ASU 2020-06 may have on its CFS and related disclosures.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]  
Schedule of depreciation of property and equipment
Leasehold improvements   7-10 years
Office furniture   5  years

 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Tables)
3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of inventory
   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Raw materials  $57,438   $60,705 
Finished goods – health supplements   141,425    146,576 
Less: inventory impairment allowance   (26,118)   (26,118)
Total  $172,745   $181,163 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, Net (Tables)
3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Leaseholder improvements  $57,067   $57,067 
Office furniture and equipment   406,241    406,241 
Total   463,308    463,308 
Less: accumulated depreciation   (233,272)   (216,929)
Net  $230,036   $246,379 

 

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets, Net (Tables)
3 Months Ended
Mar. 31, 2023
Intangible Assets, Net [Abstract]  
Schedule of Intangible assets
   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Computer Software  $36,928   $36,928 
Trademark   2,350    2,350 
Total   39,278    39,278 
Less: accumulated amortization   (38,534)   (38,476)
Net  $744   $802 

 

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities and Other Payables (Tables)
3 Months Ended
Mar. 31, 2023
Accrued Liabilities and Other Payables [Abstract]  
Schedule of accrued liabilities and other payables
   March 31,
2023
   December 31,
2022
 
   (unaudited)     
         
Accrued expenses  $6,810   $6,756 
Credit card payable   43,960    39,277 
Customer deposit   16,348    45,612 
           
Total  $67,118   $91,645 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Government Loans Payable (Tables)
3 Months Ended
Mar. 31, 2023
Government Loans Payable [Abstract]  
Schedule of future minimum loan payments
Year Ending  Amount 
   (unaudited) 
     
March 31, 2024  $4,639 
March 31, 2025   4,816 
March 31, 2026   5,000 
March 31, 2027   5,191 
March 31, 2028   5,389 
Thereafter   188,797 
Total  $213,832 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of deferred tax assets
   March 31,
2023
   December 31,
2022
 
   (unaudited)     
Net deferred tax assets:        
Bad debt expense  $1,978   $1,978 
Inventory impairment   697    697 
Operating lease charge   13,596    14,020 
Depreciation and amortization   237    237 
Expected income tax benefit from NOL carry-forwards   1,517,801    1,467,801 
Less: valuation allowance   (1,534,309)   (1,484,733)
Deferred tax assets, net of valuation allowance  $
-
   $
-
 

 

Schedule of federal statutory income tax rate and the effective income tax
   2023   2022 
   (unaudited)   (unaudited) 
Federal statutory income tax expense (benefit) rate   (21.00)%   (21.00)%
State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax   (6.98)%   (6.98)%
Change in valuation allowance   27.98%   27.98%
Effective income tax rate   
-
%   
-
%

 

Schedule of income tax expense
   2023   2022 
   (unaudited)   (unaudited) 
Income tax expense – current  $
-
   $
-
 
Income tax benefit – current   
-
    
-
 
Total income tax expense  $
        
   $
       
 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Schedule of lease costs, lease term and discount rate
   Three Months Ended
March 31,
2023
   Three Months Ended
March 31,
2022
 
   (unaudited)   (unaudited) 
Operating lease cost  $53,281   $53,281 
Weighted Average Remaining Lease Term - Operating leases including options to renew   5.51 years    6.51 years 
Weighted Average Discount Rate - Operating leases   5%   5%

 

   Three Months Ended
March 31,
2023
   Three Months Ended
March 31,
2022
 
   (unaudited)   (unaudited) 
Operating lease cost  $0.00   $4,008 
Weighted Average Remaining Lease Term - Operating leases   0.00 years    0.19 years 
Weighted Average Discount Rate - Operating leases   5%   5%

 

   Three Months Ended
March 31,
2023
 
Finance lease cost  (unaudited) 
Amortization  $3,189 
Interest on lease liabilities   645 
Total finance lease cost  $3,834 
Weighted Average Remaining Lease Term - Finance leases   3.78 
Weighted Average Discount Rate – Finance leases   5%

 

Schedule of lease liabilities
For the 12 months ending  Operating
Leases
 
   (unaudited) 
March 31, 2024  $205,848 
March 31, 2025   225,757 
March 31, 2026   225,757 
March 31, 2027   225,757 
March 31, 2028   225,757 
Thereafter   112,876 
Total undiscounted cash flows   1,221,752 
Less: imputed interest   (153,535)
Present value of lease liabilities  $1,068,217 

 

For the 12 months ending  Finance
Leases
 
   (unaudited) 
March 31, 2024  $14,890 
March 31, 2025   15,337 
March 31, 2026   11,310 
March 31, 2027   9,967 
March 31, 2028   2,492 
Total undiscounted cash flows   53,996 
Less: imputed interest   (4,900)
Present value of finance lease liabilities  $49,096 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Loan Payables (Tables)
3 Months Ended
Mar. 31, 2023
Loan Payables [Abstract]  
Schedule of maturities of loan payable
For the 12 months ending  Loan Payable 
   (unaudited) 
March 31, 2024  $15,389 
March 31, 2025   10,959 
March 31, 2026   9,974 
March 31, 2027   4,156 
Total undiscounted cash flows   40,478 
Less: imputed interest   (5,932)
Present value of loan payables  $34,546 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Description of Business (Details)
Mar. 01, 2017
Ownership [Member]  
Organization and Description of Business (Details) [Line Items]  
Shareholder, percentage 100.00%
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Accounting Policies [Abstract]    
Net losses (in Dollars) $ 178,836 $ 233,120
Bad debt allowance (in Dollars) $ 2,252 2,252
Tax benefit 50.00%  
Shipping and handling costs (in Dollars) $ 9,416 9,340
Advertising expense (in Dollars) $ 5,400 $ 1,274
One Major Customer [Member]    
Accounting Policies [Abstract]    
Total sales percentage 27.00%  
One Vendors [Member]    
Accounting Policies [Abstract]    
Concentration of credit risk 22.00% 23.00%
Two Vendors [Member]    
Accounting Policies [Abstract]    
Concentration of credit risk 20.00% 19.00%
Three Vendors [Member]    
Accounting Policies [Abstract]    
Concentration of credit risk 17.00% 10.00%
Four Vendors [Member]    
Accounting Policies [Abstract]    
Concentration of credit risk   10.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Major Customer [Member]    
Accounting Policies [Abstract]    
Concentration risk, percentage 34.00%  
Going Concern [Member]    
Accounting Policies [Abstract]    
Accumulated deficit (in Dollars) $ 8,347,431  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment
Mar. 31, 2023
Leasehold improvements [Member] | Minimum [Member]  
Public Utility, Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 7 years
Leasehold improvements [Member] | Maximum [Member]  
Public Utility, Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 10 years
Office furniture [Member]  
Public Utility, Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 5 years
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Details) - Schedule of inventory - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Schedule of Inventory [Abstract]    
Raw materials $ 57,438 $ 60,705
Finished goods – health supplements 141,425 146,576
Less: inventory impairment allowance (26,118) (26,118)
Total $ 172,745 $ 181,163
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Security Deposit (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Statistical Disclosure for Banks [Abstract]    
Security deposit $ 41,841 $ 41,841
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, Net (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation $ 16,342 $ 10,815
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, Net (Details) - Schedule of property and equipment - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, total $ 463,308 $ 463,308
Less: accumulated depreciation (233,272) (216,929)
Property and equipment, net 230,036 246,379
Leaseholder improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, total 57,067 57,067
Office furniture and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, total $ 406,241 $ 406,241
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets, Net (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible of assets $ 59 $ 6,349
Intangible assets useful life 5 years  
Amortization expense, year 1 $ 235  
Amortization expense, year 2 235  
Amortization expense, year 3 235  
Amortization expense, year 4 $ 39  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets, Net (Details) - Schedule of Intangible assets - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, total $ 39,278 $ 39,278
Less: accumulated amortization (38,534) (38,476)
Net 744 802
Trademark [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, total 2,350 2,350
Computer Software [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, total $ 36,928 $ 36,928
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Taxes Payable (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Tax Payable [Abstract]    
Sales tax and payroll tax payable $ 12,899 $ 8,392
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Schedule of accrued liabilities and other payables [Abstract]    
Accrued expenses $ 6,810 $ 6,756
Credit card payable 43,960 39,277
Customer deposit 16,348 45,612
Total $ 67,118 $ 91,645
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Government Loans Payable (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2021
Mar. 31, 2023
Dec. 31, 2021
Government Loans Payable (Details) [Line Items]      
Public private partnership loans   $ 50,000 $ 242,985
Received loans $ 115,245 2,000,000  
Handling charge   $ 100  
Interest percentage   3.75%  
Installment payments including principal and interest   $ 515  
PPP Loan [Member]      
Government Loans Payable (Details) [Line Items]      
Paycheck protection program loan   $ 127,740  
Percentage of forgiven amount   60.00%  
Annual interest, percentage   1.00%  
Economic Injury Disaster Loan [Member]      
Government Loans Payable (Details) [Line Items]      
Received loans   $ 215,600  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Government Loans Payable (Details) - Schedule of future minimum loan payments
Mar. 31, 2023
USD ($)
Schedule of future minimum loan payments [Abstract]  
March 31, 2024 $ 4,639
March 31, 2025 4,816
March 31, 2026 5,000
March 31, 2027 5,191
March 31, 2028 5,389
Thereafter 188,797
Total $ 213,832
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Senior Officer [Member]    
Related Party Transactions (Details) [Line Items]    
Officers or stockholder $ 2,758,766 $ 2,543,155
Shareholder [Member]    
Related Party Transactions (Details) [Line Items]    
Loan amount $ 608,631  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2022
Income Taxes (Details) [Line Items]          
Federal corporate income tax 21.00%        
Taxable income percentage 80.00%       80.00%
Net operating loss   80.00% 80.00% 80.00%  
Federal and California [Member]          
Income Taxes (Details) [Line Items]          
Income tax (in Dollars) $ 5,420       $ 5,250
Net deferred tax assets (in Dollars) $ 1,520        
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - Schedule of deferred tax assets - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Net deferred tax assets:    
Bad debt expense $ 1,978 $ 1,978
Inventory impairment 697 697
Operating lease charge 13,596 14,020
Depreciation and amortization 237 237
Expected income tax benefit from NOL carry-forwards 1,517,801 1,467,801
Less: valuation allowance (1,534,309) (1,484,733)
Deferred tax assets, net of valuation allowance
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - Schedule of federal statutory income tax rate and the effective income tax
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Schedule of federal statutory income tax rate and the effective income tax [Abstract]    
Federal statutory income tax expense (benefit) rate (21.00%) (21.00%)
State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax (6.98%) (6.98%)
Change in valuation allowance 27.98% 27.98%
Effective income tax rate
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - Schedule of income tax expense - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Schedule of income tax expense [Abstract]    
Income tax expense – current
Income tax benefit – current
Total income tax expense
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details) - USD ($)
3 Months Ended 4 Months Ended
Mar. 15, 2022
Oct. 01, 2018
Mar. 31, 2023
Jun. 24, 2022
Leases (Details) [Line Items]        
Lease option exercised term   62 months 15 days    
security deposits   $ 41,841    
Monthly rent   $ 16,200    
Rent percentage   3.00%    
Lease option     $ 1  
Leases One [Member]        
Leases (Details) [Line Items]        
Monthly payments     162  
Leases Two [Member]        
Leases (Details) [Line Items]        
Monthly payments     213  
Leases Three [Member]        
Leases (Details) [Line Items]        
Monthly payments $ 234   292  
Leases Four [Member]        
Leases (Details) [Line Items]        
Monthly payments $ 214   $ 669  
Lease Five [Member]        
Leases (Details) [Line Items]        
Monthly payments       $ 383
Lease Six [Member]        
Leases (Details) [Line Items]        
Monthly payments       $ 451
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details) - Schedule of lease costs, lease term and discount rate - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases (Details) - Schedule of lease costs, lease term and discount rate [Line Items]    
Amortization $ 3,189  
Interest on lease liabilities 645  
Total finance lease cost $ 3,834  
Weighted Average Remaining Lease Term - Finance leases 3 years 9 months 10 days  
Weighted Average Discount Rate – Finance leases 5.00%  
Warehouse and Office Lease [Member]    
Leases (Details) - Schedule of lease costs, lease term and discount rate [Line Items]    
Operating lease cost $ 53,281 $ 53,281
Weighted Average Remaining Lease Term - Operating leases 5 years 6 months 3 days 6 years 6 months 3 days
Weighted Average Discount Rate - Operating leases 5.00% 5.00%
Equipment leases [Member]    
Leases (Details) - Schedule of lease costs, lease term and discount rate [Line Items]    
Operating lease cost $ 0 $ 4,008
Weighted Average Remaining Lease Term - Operating leases 0 years 2 months 8 days
Weighted Average Discount Rate - Operating leases 5.00% 5.00%
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details) - Schedule of lease liabilities
3 Months Ended
Mar. 31, 2023
USD ($)
shares
Operating Leases [Member]  
Leases (Details) - Schedule of lease liabilities [Line Items]  
December 31, 2024 $ 205,848
December 31, 2025 225,757
December 31, 2026 225,757
December 31, 2027 $ 225,757
March 31, 2028 (in Shares) | shares 225,757
Thereafter $ 112,876
Total undiscounted cash flows 1,221,752
Less: imputed interest (153,535)
Present value of lease liabilities 1,068,217
Finance Lease [Member]  
Leases (Details) - Schedule of lease liabilities [Line Items]  
December 31, 2024 14,890
December 31, 2025 15,337
December 31, 2026 11,310
December 31, 2027 $ 9,967
March 31, 2028 (in Shares) | shares 2,492
Total undiscounted cash flows $ 53,996
Less: imputed interest (4,900)
Present value of lease liabilities $ 49,096
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Loan Payables (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Loan Payables [Abstract]        
Loan agreement     $ 39,218 $ 14,549
Interest rate, percentage     10.26% 14.11%
Interest expense $ 1,091 $ 1,345    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Loan Payables (Details) - Schedule of maturities of loan payable - Operating Leases [Member]
Mar. 31, 2023
USD ($)
Loan Payables (Details) - Schedule of maturities of loan payable [Line Items]  
March 31, 2024 $ 15,389
March 31, 2025 10,959
March 31, 2026 9,974
March 31, 2027 4,156
Total undiscounted cash flows 40,478
Less: imputed interest (5,932)
Present value of loan payables $ 34,546
XML 66 f10q0323_bioessen_htm.xml IDEA: XBRL DOCUMENT 0001723059 2023-01-01 2023-03-31 0001723059 2023-05-12 0001723059 2023-03-31 0001723059 2022-12-31 0001723059 cik00001723059:SalesOfGoodsMember 2023-01-01 2023-03-31 0001723059 cik00001723059:SalesOfGoodsMember 2022-01-01 2022-03-31 0001723059 cik00001723059:ManufactureServiceRevenueMember 2023-01-01 2023-03-31 0001723059 cik00001723059:ManufactureServiceRevenueMember 2022-01-01 2022-03-31 0001723059 2022-01-01 2022-03-31 0001723059 cik00001723059:CostOfGoodsSoldMember 2023-01-01 2023-03-31 0001723059 cik00001723059:CostOfGoodsSoldMember 2022-01-01 2022-03-31 0001723059 cik00001723059:CostOfManufactureServiceMember 2023-01-01 2023-03-31 0001723059 cik00001723059:CostOfManufactureServiceMember 2022-01-01 2022-03-31 0001723059 us-gaap:CommonStockMember 2022-12-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001723059 us-gaap:RetainedEarningsMember 2022-12-31 0001723059 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001723059 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001723059 us-gaap:CommonStockMember 2023-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001723059 us-gaap:RetainedEarningsMember 2023-03-31 0001723059 us-gaap:CommonStockMember 2021-12-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001723059 us-gaap:RetainedEarningsMember 2021-12-31 0001723059 2021-12-31 0001723059 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001723059 us-gaap:CommonStockMember 2022-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001723059 us-gaap:RetainedEarningsMember 2022-03-31 0001723059 2022-03-31 0001723059 cik00001723059:OwnershipMember 2017-03-01 0001723059 cik00001723059:GoingConcernMember 2023-03-31 0001723059 cik00001723059:OneMajorCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001723059 cik00001723059:OneMajorCustomerMember 2023-01-01 2023-03-31 0001723059 cik00001723059:OneVendorMember 2023-01-01 2023-03-31 0001723059 cik00001723059:TwoVendorMember 2023-01-01 2023-03-31 0001723059 cik00001723059:ThreeVendorsMember 2023-01-01 2023-03-31 0001723059 cik00001723059:OneVendorMember 2022-01-01 2022-03-31 0001723059 cik00001723059:TwoVendorMember 2022-01-01 2022-03-31 0001723059 cik00001723059:ThreeVendorsMember 2022-01-01 2022-03-31 0001723059 cik00001723059:FourVendorMember 2022-01-01 2022-03-31 0001723059 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2023-03-31 0001723059 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2023-03-31 0001723059 us-gaap:OfficeEquipmentMember 2023-03-31 0001723059 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001723059 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001723059 us-gaap:OfficeEquipmentMember 2022-12-31 0001723059 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-03-31 0001723059 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-12-31 0001723059 us-gaap:TrademarksMember 2023-03-31 0001723059 us-gaap:TrademarksMember 2022-12-31 0001723059 cik00001723059:PPPLoanMember 2023-03-31 0001723059 cik00001723059:PPPLoanMember 2023-01-01 2023-03-31 0001723059 2021-02-01 2021-02-28 0001723059 2021-01-01 2021-12-31 0001723059 cik00001723059:EconomicInjuryDisasterLoanMember 2023-01-01 2023-03-31 0001723059 cik00001723059:SeniorOfficerMember 2023-01-01 2023-03-31 0001723059 cik00001723059:SeniorOfficerMember 2022-01-01 2022-12-31 0001723059 cik00001723059:Shareholder1Member 2023-03-31 0001723059 2022-01-01 2022-12-31 0001723059 2019-01-01 2019-03-31 0001723059 2020-01-01 2020-03-31 0001723059 2021-01-01 2021-03-31 0001723059 cik00001723059:FederalAndCaliforniaMember 2023-03-31 0001723059 cik00001723059:FederalAndCaliforniaMember 2022-12-31 0001723059 2018-10-01 0001723059 2018-10-01 2018-10-01 0001723059 cik00001723059:LeasesOneMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesTwoMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesThreeMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesFourMember 2023-01-01 2023-03-31 0001723059 cik00001723059:LeasesThreeMember 2022-03-01 2022-03-15 0001723059 cik00001723059:LeasesFourMember 2022-03-01 2022-03-15 0001723059 cik00001723059:LeaseFiveMember 2022-03-01 2022-06-24 0001723059 cik00001723059:LeaseSixMember 2022-03-01 2022-06-24 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2023-01-01 2023-03-31 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2022-01-01 2022-03-31 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2023-03-31 0001723059 cik00001723059:WarehouseAndOfficeLeaseMember 2022-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2023-01-01 2023-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2022-01-01 2022-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2023-03-31 0001723059 cik00001723059:EquipmentLeasesMember 2022-03-31 0001723059 cik00001723059:OperatingLeasesMember 2023-03-31 0001723059 cik00001723059:OperatingLeasesMember 2023-01-01 2023-03-31 0001723059 cik00001723059:FinanceLeaseMember 2023-03-31 0001723059 cik00001723059:FinanceLeaseMember 2023-01-01 2023-03-31 0001723059 2021-06-30 0001723059 2021-09-30 0001723059 cik00001723059:OperatingLeaseMember 2023-03-31 shares iso4217:USD iso4217:USD shares pure 10-Q true 2023-03-31 2023 false 333-232839 CA 94-3349551 8 Studebaker Drive in Irvine CA 92618 (949) 706-9966 Yes Yes Non-accelerated Filer true true true N/A N/A false 33009000 127 6262 10700 5599 8630 8820 61573 1987 172745 181163 253775 203831 41841 41841 1015457 1054872 230036 246379 744 802 1288078 1343894 1541853 1547725 70860 53651 58334 49776 12899 8392 67118 91645 16805 16867 160176 156560 12761 12603 12311 11954 4639 4596 3367397 3151786 3783300 3557830 908040 952756 36335 39687 22236 25561 209193 210306 1175804 1228310 4959104 4786140 0.0001 0.0001 10000000 10000000 0.0001 0.0001 100000000 100000000 33009000 33009000 33009000 33009000 3301 3301 4926879 4926879 -8347431 -8168595 -3417251 -3238415 1541853 1547725 149760 181579 191569 124835 341329 306414 70500 145665 104307 90293 174807 235958 166522 70456 35712 10614 304994 286274 340706 296888 -174184 -226432 5824 5160 -976 -1568 2497 535 349 495 -4652 -6688 -178836 -233120 -178836 -233120 33009000 33009000 -0.01 -0.01 33009000 3301 4926879 -8168595 -3238415 -178836 -178836 33009000 3301 4926879 -8347431 -3417251 33009000 3301 4926879 -7358916 -2428736 -233120 -233120 33009000 3301 4926879 -7592036 -2661856 -178836 -233120 16401 10874 53110 57717 5103 31539 -190 5536 -59586 -10636 -8419 45442 8558 28291 -29264 4738 27804 62 4507 4319 -54795 -57207 -231723 -254475 17209 8367 3193 1071 2968 3970 215611 250000 225588 254397 -6135 -78 6262 303 127 225 5883 6098 16077 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Bio Essence Corporation (“the Company” or “Bio Essence”) was incorporated in 2000 in the state of California. Fusion Diet Systems (“FDS”) was incorporated in 2010 in the state of Utah. Bio Essence and FDS were under common control since 2016. Bio Essence and FDS are mainly engaged in manufacturing and distributing health supplement products. In January 2017, Bio Essence incorporated two subsidiaries in the state of California: Bio Essence Pharmaceutical Inc. (“BEP”) and Bio Essence Herbal Essentials, Inc. (“BEH”), Bio Essence transferred its manufacturing operation to BEP, and transferred its distributing operation to BEH. On March 1, 2017, the 100% shareholder of FDS transferred all of her ownership in FDS to Bio Essence. On December 7, 2021, the Company dissolved FDS. On November 12, 2021, Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in developing, manufacturing and sales of prescription medicine. As a result of the ownership restructure, BEP BEH and McBE became wholly owned subsidiaries of Bio Essence. McBE has not engaged any operations since its inception.</span></p> 1 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basis of Presentation and Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><span>The interim consolidated financial information as of March 31, 2023 and for the three-month periods ended March 31 30, 2023 and 2022 was prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures, which are normally included in CFS prepared in accordance with U.S. GAAP were not included. The interim consolidated financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify"><span>In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of March 31, 2023, its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022, as applicable, were made. The results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2023 or for any future period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Reclassification</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Certain prior period accounts have been reclassified in conformity with current period’s presentation. These reclassifications had no impact on the reported results of operations and cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Going Concern</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company incurred net losses of $178,836 and $233,120 for the three months ended March 31, 2023 and 2022, respectively. The Company also had an accumulated deficit of $8,347,431 as of March 31, 2023. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s consolidated balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company elected the package of practical expedients permitted under the transition guidance to combine the lease and non-lease components as a single lease component for operating leases associated with the Company’s office space lease, and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. The Company recognized no impairment of ROU assets as of March 31, 2023 and December 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cash and Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Accounts Receivable</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2023 and December 31, 2022, the bad debt allowance was $2,252 and $2,252, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Inventory</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Inventories are stated at the lower of cost or net realizable value with cost determined on a weighted-average basis. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down their inventories to net realizable value, if lower.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Property and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Leasehold improvements</span></td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 12%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">7-10 years</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Office furniture</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">5  years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Impairment of Long-Lived Assets</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of March 31, 2023 and December 31, 2022, there was no significant impairments of its long-lived assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Income taxes are accounted for using an asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets also include the prior years’ net operating losses carried forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At March 31, 2023 and December 31, 2022, the Company did not take any uncertain positions that would necessitate recording a tax related liability. The Company files a U.S. income tax return. With few exceptions, the Company’s U.S. income tax return filed for the years ending on December 31, 2019 and thereafter are subject to examination by the relevant taxing authorities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><br/> The Company accounts for income taxes in interim periods in accordance with FASB ASC 740-270, “Interim Reporting.” The Company has determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during the Company’s fiscal year to its best current estimate. The estimated annual effective tax rate is applied to the year-to-date ordinary income (or loss) at the end of the interim period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Revenue Recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the manufactured goods were delivered to the customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cost of Revenue</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Cost of goods sold (“COGS”) consists primarily of finished goods purchased from other manufacturers, material costs, labor costs and related overhead that are directly attributable to the production of the products. Write-down of inventory to lower of cost or net realizable value is also recorded in COGS.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Cost of manufacture service consists primarily of direct labor costs and related overhead that are directly attributable to the manufacture process.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Shipping and Handling Costs</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Shipping and handling costs related to delivery of finished goods are included in selling expenses. During the three months ended March 31, 2023 and 2022, shipping and handling costs were $9,416 and <span style="-sec-ix-hidden: hidden-fact-22">$9</span><span style="font-family: Times New Roman, Times, Serif">,340</span>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Advertising</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Advertising expenses consist primarily of costs of promotion and marketing for the Company’s image and products, and costs of direct advertising, and are included in selling expenses. The Company expenses all advertising costs as incurred. During the three months ended March 31, 2023 and 2022, advertising expense was $5,400 and $1,274, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value (“FV”) of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value Measurements and Disclosures</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of March 31, 2023 and December 31, 2022, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV. The carrying value of cash, accounts receivable, prepaid expenses, advances to suppliers, accounts payable, taxes payable, other payables and accrued liabilities approximate estimated fair values because of their short maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Share-based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for share-based compensation awards in accordance with ASC 718, “Compensation – Stock Compensation”. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date and amortized on a straight-line basis over the requisite service period or vesting period. The Company records forfeitures as they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Earnings (Loss) per Share (EPS)</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed similar to basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if all the potential common shares pertaining to warrants, stock options, and similar instruments had been issued and if the additional common shares were dilutive. Diluted EPS are based on the assumption that all dilutive convertible shares and stock options and warrants were converted or exercised. Dilution is computed by applying the treasury stock method for the outstanding unvested restricted stock, options and warrants, and the if-converted method for the outstanding convertible instruments. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later) and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, outstanding convertible instruments are assumed to be converted into common stock at the beginning of the period (or at the time of issuance, if later). There were no potentially dilutive securities outstanding (options and warrants) for the three months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For the three months ended March 31, 2023, the company had one major customer accounted for 34% of the Company’s total sales. For the three months ended March 31, 2022, the company had one major customer accounted for 27% of the Company’s total sales.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company had three major vendors accounted for 22%, 20%, and 17% respectively, of total purchases during the three months ended March 31, 2023. The Company had four major vendors accounted for 23%, 19%, 10% and 10%, respectively, of total purchases during the three months ended March 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Segment Reporting</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: manufacture and sale of health supplement products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>New Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i><span style="text-decoration:underline">Recently issued accounting pronouncements not yet adopted</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company is currently evaluating the impact that ASU 2020-06 may have on its CFS and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basis of Presentation and Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><span>The interim consolidated financial information as of March 31, 2023 and for the three-month periods ended March 31 30, 2023 and 2022 was prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures, which are normally included in CFS prepared in accordance with U.S. GAAP were not included. The interim consolidated financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify"><span>In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of March 31, 2023, its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022, as applicable, were made. The results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2023 or for any future period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Reclassification</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Certain prior period accounts have been reclassified in conformity with current period’s presentation. These reclassifications had no impact on the reported results of operations and cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Going Concern</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company incurred net losses of $178,836 and $233,120 for the three months ended March 31, 2023 and 2022, respectively. The Company also had an accumulated deficit of $8,347,431 as of March 31, 2023. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 178836 233120 8347431 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s consolidated balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company elected the package of practical expedients permitted under the transition guidance to combine the lease and non-lease components as a single lease component for operating leases associated with the Company’s office space lease, and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. The Company recognized no impairment of ROU assets as of March 31, 2023 and December 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cash and Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Accounts Receivable</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2023 and December 31, 2022, the bad debt allowance was $2,252 and $2,252, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 2252 2252 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Inventory</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Inventories are stated at the lower of cost or net realizable value with cost determined on a weighted-average basis. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down their inventories to net realizable value, if lower.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Property and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Leasehold improvements</span></td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 12%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">7-10 years</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Office furniture</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">5  years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Leasehold improvements</span></td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 12%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">7-10 years</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Office furniture</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">5  years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> P7Y P10Y P5Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Impairment of Long-Lived Assets</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of March 31, 2023 and December 31, 2022, there was no significant impairments of its long-lived assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Income taxes are accounted for using an asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets also include the prior years’ net operating losses carried forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At March 31, 2023 and December 31, 2022, the Company did not take any uncertain positions that would necessitate recording a tax related liability. The Company files a U.S. income tax return. With few exceptions, the Company’s U.S. income tax return filed for the years ending on December 31, 2019 and thereafter are subject to examination by the relevant taxing authorities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><br/> The Company accounts for income taxes in interim periods in accordance with FASB ASC 740-270, “Interim Reporting.” The Company has determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during the Company’s fiscal year to its best current estimate. The estimated annual effective tax rate is applied to the year-to-date ordinary income (or loss) at the end of the interim period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Revenue Recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the manufactured goods were delivered to the customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cost of Revenue</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Cost of goods sold (“COGS”) consists primarily of finished goods purchased from other manufacturers, material costs, labor costs and related overhead that are directly attributable to the production of the products. Write-down of inventory to lower of cost or net realizable value is also recorded in COGS.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Cost of manufacture service consists primarily of direct labor costs and related overhead that are directly attributable to the manufacture process.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Shipping and Handling Costs</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Shipping and handling costs related to delivery of finished goods are included in selling expenses. During the three months ended March 31, 2023 and 2022, shipping and handling costs were $9,416 and <span style="-sec-ix-hidden: hidden-fact-22">$9</span><span style="font-family: Times New Roman, Times, Serif">,340</span>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 9416 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Advertising</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Advertising expenses consist primarily of costs of promotion and marketing for the Company’s image and products, and costs of direct advertising, and are included in selling expenses. The Company expenses all advertising costs as incurred. During the three months ended March 31, 2023 and 2022, advertising expense was $5,400 and $1,274, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 5400 1274 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value (“FV”) of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value Measurements and Disclosures</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of March 31, 2023 and December 31, 2022, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV. The carrying value of cash, accounts receivable, prepaid expenses, advances to suppliers, accounts payable, taxes payable, other payables and accrued liabilities approximate estimated fair values because of their short maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Share-based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for share-based compensation awards in accordance with ASC 718, “Compensation – Stock Compensation”. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date and amortized on a straight-line basis over the requisite service period or vesting period. The Company records forfeitures as they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Earnings (Loss) per Share (EPS)</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed similar to basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if all the potential common shares pertaining to warrants, stock options, and similar instruments had been issued and if the additional common shares were dilutive. Diluted EPS are based on the assumption that all dilutive convertible shares and stock options and warrants were converted or exercised. Dilution is computed by applying the treasury stock method for the outstanding unvested restricted stock, options and warrants, and the if-converted method for the outstanding convertible instruments. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later) and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, outstanding convertible instruments are assumed to be converted into common stock at the beginning of the period (or at the time of issuance, if later). There were no potentially dilutive securities outstanding (options and warrants) for the three months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For the three months ended March 31, 2023, the company had one major customer accounted for 34% of the Company’s total sales. For the three months ended March 31, 2022, the company had one major customer accounted for 27% of the Company’s total sales.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company had three major vendors accounted for 22%, 20%, and 17% respectively, of total purchases during the three months ended March 31, 2023. The Company had four major vendors accounted for 23%, 19%, 10% and 10%, respectively, of total purchases during the three months ended March 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.34 0.27 0.22 0.20 0.17 0.23 0.19 0.10 0.10 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Segment Reporting</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: manufacture and sale of health supplement products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>New Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i><span style="text-decoration:underline">Recently issued accounting pronouncements not yet adopted</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company is currently evaluating the impact that ASU 2020-06 may have on its CFS and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>3. INVENTORY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Inventory consisted of the following at March 31, 2023 and December 31, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,438</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,705</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Finished goods – health supplements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">141,425</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146,576</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: inventory impairment allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">172,745</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">181,163</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,438</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,705</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Finished goods – health supplements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">141,425</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146,576</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: inventory impairment allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">172,745</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">181,163</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 57438 60705 141425 146576 26118 26118 172745 181163 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>4. SECURITY DEPOSIT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of March 31, 2023 and December 31, 2022, the security deposit was for rent of the Company’s office and warehouse of $41,841.</span></p> 41841 41841 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>5. PROPERTY AND EQUIPMENT, NET</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Property and equipment consisted of the following at March 31, 2023 and December 31, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Leaseholder improvements</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,067</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,067</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">406,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">406,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">463,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">463,308</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(233,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(216,929</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">230,036</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">246,379</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Depreciation for the three months ended March 31, 2023 and 2022 was $16,342 and $10,815, respectively.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Leaseholder improvements</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,067</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,067</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">406,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">406,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">463,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">463,308</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(233,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(216,929</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">230,036</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">246,379</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 57067 57067 406241 406241 463308 463308 233272 216929 230036 246379 16342 10815 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>6. INTANGIBLE ASSETS, NET</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Intangible assets consisted of the following as of March 31, 2023 and December 31, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Computer Software</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,928</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Trademark</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,278</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,534</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,476</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">744</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Amortization of intangible assets was $59 and $6,349 for the three months ended March 31, 2023 and 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Estimated amortization for the existing intangible assets with finite lives for each of the next five years at March 31, 2023 is as follows: $235, $235, $235 and $39.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Computer Software</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,928</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Trademark</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,278</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,534</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,476</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">744</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 36928 36928 2350 2350 39278 39278 -38534 -38476 744 802 59 6349 P5Y 235 235 235 39 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>7. TAXES PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Taxes payable at March 31 2023, and December 31, 2022, was for sales tax and payroll tax payable of $12,899 and $8,392, respectively.</span></p> 12899 8392 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>8. ACCRUED LIABILITIES AND OTHER PAYABLES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Accrued liabilities and other payables consisted of the following March 31, 2023 and December 31, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Accrued expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,756</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Credit card payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,277</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Customer deposit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,348</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,612</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">67,118</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,645</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Accrued expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,756</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Credit card payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,277</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Customer deposit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,348</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,612</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">67,118</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,645</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 6810 6756 43960 39277 16348 45612 67118 91645 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>9. GOVERNMENT LOANS PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In May and June 2020, BEH, BEP and FDS received a total of $127,740 from the Paycheck Protection Program loan (“PPP loan”) from US Small Business Administration (“the SBA”). The loan will be fully forgiven if the funds are used for payroll costs, interest on mortgages, rent, and utilities (at least 60% of the forgiven amount must have been used for payroll). The loan amount not forgiven, will have annual interest of 1%. Loan payments will be deferred to either (1) the date that SBA remits the borrower’s loan forgiveness amount to the lender or (2) if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness covered period. Loans issued prior to June 5, 2020 have a maturity of two years, loans issued after June 5, 2020 have a maturity of five years. No collateral or personal guarantees are required. A borrower may apply for loan forgiveness any time on or before the maturity date of the loan, including before the end of the Covered Period (either (1) the 24-week (168-day) period beginning on the PPP Loan Disbursement Date, or (2) if the Borrower received its PPP loan before June 5, 2020, the Borrower may elect to use an eight-week (56-day) Covered Period); provided such application for loan forgiveness is made within 10 months after the last day of the covered period, otherwise the loan is no longer deferred and the borrower must begin paying principal and interest. Subsequently, The U.S. Treasury and SBA announced a streamlined PPP forgiveness application for loans of $50,000 or less (unless those borrowers together with their affiliates received loans totaling $2 million or more). It requires fewer calculations and may call for less documentation. It does not require borrowers to reduce their loan forgiveness calculations if they have reduced full-time equivalent (“FTE”) or salaries. In addition, in February 2021, BEH, BEP and FDS received a total of $115,245 from the second round of PPP loan from the SBA. As of December 31, 2021, all BEH, BEP and FDS’ PPP loans’ forgiveness were approved and the Company recorded $242,985 PPP loan forgiveness as other income in the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In May and June 2020, BEH, BEP and FDS received total of $215,600 from the Economic Injury Disaster Loan (“EIDL loan”) from the SBA after deducting $100 Uniform Commercial Code (“UCC”) handling charge and filing fee for each company. This is a low-interest federal disaster loan for working capital to small businesses and non-profit organizations of any size suffering substantial economic injury as a result of the Coronavirus (COVID-19), to help the businesses to meet financial obligations and operating expenses that could have been met had the disaster not occurred. This loan has interest of 3.75% and is not forgivable. The maturity of the loan is 30 years, installment payments including principal and interest of $515 monthly will begin 12 months from the date of the promissory note. On March 4, 2022, The FDS transferred its EIDL loan to BEC due to the dissolution of FDS. The SBA extended the deferment period to allow small businesses and not-for-profits that received EIDL funds do not have to begin payments on the loan until 30 months after the date of the note. Accordingly, the company began to make installment payments in the fourth quarter 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of March 31, 2023, the future minimum EIDL loan payments to be paid by year are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year Ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,639</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,816</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,389</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">188,797</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,832</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 127740 0.60 0.01 50000 2000000 115245 242985 215600 100 0.0375 515 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year Ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,639</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,816</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,389</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">188,797</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,832</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 4639 4816 5000 5191 5389 188797 213832 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>10. RELATED PARTY TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i><span style="text-decoration:underline">Loans from Shareholder</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At March 31, 2023 and December 31, 2022, the Company had loans from one major shareholder (also the Company’s senior officer) for $2,758,766 and $<span style="-sec-ix-hidden: hidden-fact-23">2,543155</span>, respectively. At March 31, 2023 and December, 2022, the Company had loan from another major shareholder for $608,631 for settling the litigation. There are no written loan agreements for these loans. These loans are unsecured, non-interest bearing and have no fixed terms of repayment, and therefore, deemed payable on demand. Cash flows from loans form shareholder are classified as cash flows from financing activities.</span></p> 2758766 608631 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>11. INCOME TAXES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company and its subsidiaries are subject to 21% federal corporate income tax in US.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At March 31, 2023 and December, 2022, the Company had net operating loss (“NOL”) for income tax purposes; for federal income tax purposes, the NOL arising in tax years beginning after 2017 may only reduce 80% of a taxpayer’s taxable income, and may be carried forward indefinitely; for California income tax purposes, the entire NOL can be carried forward up to 20 years. However, the coronavirus Aid, Relief and Economic Security Act (“the CARES Act”) issued in March 2020, provides tax relief to both corporate and noncorporate taxpayers by adding a five-year carryback period and temporarily repealing the 80% limitation for NOLs arising in 2019, 2020 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company has NOL carry-forwards for Federal and California income tax purposes of $5.42 million and $5.25 million at March 31, 2023 and December 31, 2022, respectively. No tax benefit was reported with respect to these NOL carry-forwards in the accompanying consolidated financial statements because the Company believes the realization of the Company’s net deferred tax assets for the NOL for both federal and California State of approximately $1.52 million as of March 31, 2023, was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are fully offset by a full valuation allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Components of the Company’s deferred tax assets as of March 31, 2023 and December 31, 2022 are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net deferred tax assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Bad debt expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,978</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,978</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Inventory impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease charge</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,596</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected income tax benefit from NOL carry-forwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,517,801</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,467,801</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,534,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,484,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Deferred tax assets, net of valuation allowance</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i><span style="text-decoration:underline">Income Tax Provision in the Statements of Operations</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>A reconciliation of the consolidated federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes for the three months ended March 31, 2023 and 2022 is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Federal statutory income tax expense (benefit) rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6.98</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6.98</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27.98</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27.98</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Effective income tax rate</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The provision for income tax expense for the three months ended March 31, 2023 and 2022 consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Income tax expense – current</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Income tax benefit – current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total income tax expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">        </div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">       </div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 0.21 0.80 0.80 0.80 0.80 0.80 5420000 5250000 1520000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net deferred tax assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Bad debt expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,978</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,978</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Inventory impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease charge</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,596</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected income tax benefit from NOL carry-forwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,517,801</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,467,801</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,534,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,484,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Deferred tax assets, net of valuation allowance</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 1978 1978 697 697 13596 14020 237 237 1517801 1467801 1534309 1484733 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Federal statutory income tax expense (benefit) rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6.98</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6.98</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27.98</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27.98</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Effective income tax rate</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.21 0.21 -0.0698 -0.0698 0.2798 0.2798 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Income tax expense – current</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Income tax benefit – current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total income tax expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">        </div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">       </div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>12. LEASES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><span style="text-decoration:underline">Operating Leases</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i><span style="text-decoration:underline">Warehouse and office lease</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Effective October 1, 2018, the Company entered a 62.5 months lease for a facility including warehouse and office in the City of Irvine, California, with a security deposit of $41,841. The monthly rent is approximately $16,200 with a 3% increase each year. The lease provided an option to extend at lease maturity for another five-years, with six months prior written notice of lessee’s intention to extend the lease. The Company’s CEO is the guarantor of this lease. Lessor will have the right to proceed against guarantor following any breach or default by lessee without first proceeding against lessee and without previous notice to or demand upon either lessee or guarantor.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The components of lease costs, lease term and discount rate with respect of warehouse and office lease in the City of Irvine with an initial term of more than 12 months are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">53,281</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">53,281</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted Average Remaining Lease Term - Operating leases including options to renew</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.51 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">6.51 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted Average Discount Rate - Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The following is a schedule, by years, of maturities of warehouse and office lease liabilities as of March 31, 2023:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the 12 months ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205,848</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">112,876</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,221,752</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(153,535</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,068,217</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i><span style="text-decoration:underline">Equipment leases</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In 2017, the Company entered two leases for two copiers with terms of 60 and 63 months respectively, and monthly payments of $162 and $213, respectively. The Company also entered two leases for two forklifts with a term of 60 months for each, and the monthly payment was $292 and $669, respectively. All these equipment lease expired in 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The components of lease costs, lease term and discount rate with respect of these equipment leases are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0.00</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4,008</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Weighted Average Remaining Lease Term - Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">0.00 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">0.19 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted Average Discount Rate - Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><span style="text-decoration:underline">Finance lease</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Effective March 15, 2022, the company entered two 39-months lease for two copiers with same vendor for a monthly payment of $234 and $214, respectively. Effective June 24, 2022, the company entered two leases for two forklifts with a term of 60 months for each, and the monthly payment was $383 and $451, respectively. At the lease expiration date, the Company has the option to purchase the copier for $1 each.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The components of lease costs, lease term and discount rate with respect of the copier lease with an initial term of more than 12 months are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Finance lease cost</td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; padding-left: 9pt">Amortization</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,189</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">645</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total finance lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,834</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Weighted Average Remaining Lease Term - Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.78</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted Average Discount Rate – Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The following is a schedule, by years, of maturities of finance lease liabilities as of March 31, 2023:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the 12 months ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,890</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,337</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,967</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">March 31, 2028</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,492</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,996</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,900</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Present value of finance lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,096</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> P62M15D 41841 16200 0.03 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">53,281</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">53,281</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted Average Remaining Lease Term - Operating leases including options to renew</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.51 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">6.51 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted Average Discount Rate - Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0.00</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4,008</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Weighted Average Remaining Lease Term - Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">0.00 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">0.19 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted Average Discount Rate - Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Finance lease cost</td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; padding-left: 9pt">Amortization</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,189</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">645</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total finance lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,834</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Weighted Average Remaining Lease Term - Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.78</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted Average Discount Rate – Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 53281 53281 P5Y6M3D P6Y6M3D 0.05 0.05 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the 12 months ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205,848</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,757</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">112,876</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,221,752</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(153,535</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,068,217</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the 12 months ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,890</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,337</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,967</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">March 31, 2028</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,492</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,996</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,900</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Present value of finance lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,096</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 205848 225757 225757 225757 225757 112876 1221752 153535 1068217 162 213 292 669 0 4008 P0Y P0Y2M8D 0.05 0.05 234 214 383 451 1 3189 645 3834 P3Y9M10D 0.05 14890 15337 11310 9967 2492 53996 4900 49096 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>13. LOAN PAYABLES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In June 2021, the Company entered a loan agreement of $14,549 for purchasing a videojet with interest rate of 14.11% and a term of three-years. In September 2021, the Company entered another loan agreement of $39,218 for purchasing a spectrophotometer workstation with interest rate of 10.26% and a term of five-years. The Company recorded interest expense of $1,091 and $1,345 during the three months ended March 31, 2023 and 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The following is a schedule, by years, of maturities of loan payable as of March31, 2023:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the 12 months ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loan Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,389</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,959</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,974</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,156</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,478</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Present value of loan payables</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">34,546</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 14549 0.1411 39218 0.1026 1091 1345 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the 12 months ending</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loan Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">(unaudited)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,389</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,959</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,974</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">March 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,156</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,478</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Present value of loan payables</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">34,546</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 15389 10959 9974 4156 40478 -5932 34546 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>14. SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company did not have any material subsequent event.</span></p> --12-31 Bio Essence Corp NONE 33009000 33009000 -0.01 -0.01 9340 2543155 false Q1 0001723059 EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end
XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 91 261 1 false 38 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.bioessencecorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Operations (Unaudited) (Parentheticals) Sheet http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Operations (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Stockholders??? Deficit (Unaudited) Sheet http://www.bioessencecorp.com/role/ShareholdersEquityType2or3 Consolidated Statements of Stockholders??? Deficit (Unaudited) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bioessencecorp.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Organization and Description of Business Sheet http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Inventory Sheet http://www.bioessencecorp.com/role/Inventory Inventory Notes 10 false false R11.htm 010 - Disclosure - Security Deposit Sheet http://www.bioessencecorp.com/role/SecurityDeposit Security Deposit Notes 11 false false R12.htm 011 - Disclosure - Property and Equipment, Net Sheet http://www.bioessencecorp.com/role/PropertyandEquipmentNet Property and Equipment, Net Notes 12 false false R13.htm 012 - Disclosure - Intangible Assets, Net Sheet http://www.bioessencecorp.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 13 false false R14.htm 013 - Disclosure - Taxes Payable Sheet http://www.bioessencecorp.com/role/TaxesPayable Taxes Payable Notes 14 false false R15.htm 014 - Disclosure - Accrued Liabilities and Other Payables Sheet http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayables Accrued Liabilities and Other Payables Notes 15 false false R16.htm 015 - Disclosure - Government Loans Payable Sheet http://www.bioessencecorp.com/role/GovernmentLoansPayable Government Loans Payable Notes 16 false false R17.htm 016 - Disclosure - Related Party Transactions Sheet http://www.bioessencecorp.com/role/RelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 017 - Disclosure - Income Taxes Sheet http://www.bioessencecorp.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Leases Sheet http://www.bioessencecorp.com/role/Leases Leases Notes 19 false false R20.htm 019 - Disclosure - Loan Payables Sheet http://www.bioessencecorp.com/role/LoanPayables Loan Payables Notes 20 false false R21.htm 020 - Disclosure - Subsequent Events Sheet http://www.bioessencecorp.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 021 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPolicies 22 false false R23.htm 022 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPolicies 23 false false R24.htm 023 - Disclosure - Inventory (Tables) Sheet http://www.bioessencecorp.com/role/InventoryTables Inventory (Tables) Tables http://www.bioessencecorp.com/role/Inventory 24 false false R25.htm 024 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.bioessencecorp.com/role/PropertyandEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.bioessencecorp.com/role/PropertyandEquipmentNet 25 false false R26.htm 025 - Disclosure - Intangible Assets, Net (Tables) Sheet http://www.bioessencecorp.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://www.bioessencecorp.com/role/IntangibleAssetsNet 26 false false R27.htm 026 - Disclosure - Accrued Liabilities and Other Payables (Tables) Sheet http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayablesTables Accrued Liabilities and Other Payables (Tables) Tables http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayables 27 false false R28.htm 027 - Disclosure - Government Loans Payable (Tables) Sheet http://www.bioessencecorp.com/role/GovernmentLoansPayableTables Government Loans Payable (Tables) Tables http://www.bioessencecorp.com/role/GovernmentLoansPayable 28 false false R29.htm 028 - Disclosure - Income Taxes (Tables) Sheet http://www.bioessencecorp.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bioessencecorp.com/role/IncomeTaxes 29 false false R30.htm 029 - Disclosure - Leases (Tables) Sheet http://www.bioessencecorp.com/role/LeasesTables Leases (Tables) Tables http://www.bioessencecorp.com/role/Leases 30 false false R31.htm 030 - Disclosure - Loan Payables (Tables) Sheet http://www.bioessencecorp.com/role/LoanPayablesTables Loan Payables (Tables) Tables http://www.bioessencecorp.com/role/LoanPayables 31 false false R32.htm 031 - Disclosure - Organization and Description of Business (Details) Sheet http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusiness 32 false false R33.htm 032 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesTables 33 false false R34.htm 033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment Sheet http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable Summary of Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment Details http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesTables 34 false false R35.htm 034 - Disclosure - Inventory (Details) - Schedule of inventory Sheet http://www.bioessencecorp.com/role/ScheduleofinventoryTable Inventory (Details) - Schedule of inventory Details http://www.bioessencecorp.com/role/InventoryTables 35 false false R36.htm 035 - Disclosure - Security Deposit (Details) Sheet http://www.bioessencecorp.com/role/SecurityDepositDetails Security Deposit (Details) Details http://www.bioessencecorp.com/role/SecurityDeposit 36 false false R37.htm 036 - Disclosure - Property and Equipment, Net (Details) Sheet http://www.bioessencecorp.com/role/PropertyandEquipmentNetDetails Property and Equipment, Net (Details) Details http://www.bioessencecorp.com/role/PropertyandEquipmentNetTables 37 false false R38.htm 037 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment Sheet http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable Property and Equipment, Net (Details) - Schedule of property and equipment Details http://www.bioessencecorp.com/role/PropertyandEquipmentNetTables 38 false false R39.htm 038 - Disclosure - Intangible Assets, Net (Details) Sheet http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails Intangible Assets, Net (Details) Details http://www.bioessencecorp.com/role/IntangibleAssetsNetTables 39 false false R40.htm 039 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible assets Sheet http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable Intangible Assets, Net (Details) - Schedule of Intangible assets Details http://www.bioessencecorp.com/role/IntangibleAssetsNetTables 40 false false R41.htm 040 - Disclosure - Taxes Payable (Details) Sheet http://www.bioessencecorp.com/role/TaxesPayableDetails Taxes Payable (Details) Details http://www.bioessencecorp.com/role/TaxesPayable 41 false false R42.htm 041 - Disclosure - Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables Sheet http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables Details http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayablesTables 42 false false R43.htm 042 - Disclosure - Government Loans Payable (Details) Sheet http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails Government Loans Payable (Details) Details http://www.bioessencecorp.com/role/GovernmentLoansPayableTables 43 false false R44.htm 043 - Disclosure - Government Loans Payable (Details) - Schedule of future minimum loan payments Sheet http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable Government Loans Payable (Details) - Schedule of future minimum loan payments Details http://www.bioessencecorp.com/role/GovernmentLoansPayableTables 44 false false R45.htm 044 - Disclosure - Related Party Transactions (Details) Sheet http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.bioessencecorp.com/role/RelatedPartyTransactions 45 false false R46.htm 045 - Disclosure - Income Taxes (Details) Sheet http://www.bioessencecorp.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bioessencecorp.com/role/IncomeTaxesTables 46 false false R47.htm 046 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets Sheet http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable Income Taxes (Details) - Schedule of deferred tax assets Details http://www.bioessencecorp.com/role/IncomeTaxesTables 47 false false R48.htm 047 - Disclosure - Income Taxes (Details) - Schedule of federal statutory income tax rate and the effective income tax Sheet http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable Income Taxes (Details) - Schedule of federal statutory income tax rate and the effective income tax Details http://www.bioessencecorp.com/role/IncomeTaxesTables 48 false false R49.htm 048 - Disclosure - Income Taxes (Details) - Schedule of income tax expense Sheet http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable Income Taxes (Details) - Schedule of income tax expense Details http://www.bioessencecorp.com/role/IncomeTaxesTables 49 false false R50.htm 049 - Disclosure - Leases (Details) Sheet http://www.bioessencecorp.com/role/LeasesDetails Leases (Details) Details http://www.bioessencecorp.com/role/LeasesTables 50 false false R51.htm 050 - Disclosure - Leases (Details) - Schedule of lease costs, lease term and discount rate Sheet http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable Leases (Details) - Schedule of lease costs, lease term and discount rate Details http://www.bioessencecorp.com/role/LeasesTables 51 false false R52.htm 051 - Disclosure - Leases (Details) - Schedule of lease liabilities Sheet http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable Leases (Details) - Schedule of lease liabilities Details http://www.bioessencecorp.com/role/LeasesTables 52 false false R53.htm 052 - Disclosure - Loan Payables (Details) Sheet http://www.bioessencecorp.com/role/LoanPayablesDetails Loan Payables (Details) Details http://www.bioessencecorp.com/role/LoanPayablesTables 53 false false R54.htm 053 - Disclosure - Loan Payables (Details) - Schedule of maturities of loan payable Sheet http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable Loan Payables (Details) - Schedule of maturities of loan payable Details http://www.bioessencecorp.com/role/LoanPayablesTables 54 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: cik00001723059:DueFromOfficersOrStockholder, cik00001723059:ShippingAndHandlingCosts, dei:EntityRegistrantName, dei:SecurityExchangeName, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10q0323_bioessen.htm 3424, 3425, 3432, 3433, 3434, 3435, 3445, 3446 f10q0323_bioessen.htm cik00001723059-20230331.xsd cik00001723059-20230331_cal.xml cik00001723059-20230331_def.xml cik00001723059-20230331_lab.xml cik00001723059-20230331_pre.xml f10q0323ex31-1_bioessence.htm f10q0323ex31-2_bioessence.htm f10q0323ex32-1_bioessence.htm f10q0323ex32-2_bioessence.htm image_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0323_bioessen.htm": { "axisCustom": 1, "axisStandard": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 345, "http://xbrl.sec.gov/dei/2023": 31 }, "contextCount": 91, "dts": { "calculationLink": { "local": [ "cik00001723059-20230331_cal.xml" ] }, "definitionLink": { "local": [ "cik00001723059-20230331_def.xml" ] }, "inline": { "local": [ "f10q0323_bioessen.htm" ] }, "labelLink": { "local": [ "cik00001723059-20230331_lab.xml" ] }, "presentationLink": { "local": [ "cik00001723059-20230331_pre.xml" ] }, "schema": { "local": [ "cik00001723059-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 438, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 26, "http://www.bioessencecorp.com/20230331": 5, "http://xbrl.sec.gov/dei/2023": 6, "total": 37 }, "keyCustom": 58, "keyStandard": 203, "memberCustom": 27, "memberStandard": 11, "nsprefix": "cik00001723059", "nsuri": "http://www.bioessencecorp.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:TradingSymbol", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.bioessencecorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:TradingSymbol", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Inventory", "menuCat": "Notes", "order": "10", "role": "http://www.bioessencecorp.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Security Deposit", "menuCat": "Notes", "order": "11", "role": "http://www.bioessencecorp.com/role/SecurityDeposit", "shortName": "Security Deposit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Property and Equipment, Net", "menuCat": "Notes", "order": "12", "role": "http://www.bioessencecorp.com/role/PropertyandEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Intangible Assets, Net", "menuCat": "Notes", "order": "13", "role": "http://www.bioessencecorp.com/role/IntangibleAssetsNet", "shortName": "Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:TaxPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Taxes Payable", "menuCat": "Notes", "order": "14", "role": "http://www.bioessencecorp.com/role/TaxesPayable", "shortName": "Taxes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:TaxPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:AccruedLiabilitiesAndOtherPayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Accrued Liabilities and Other Payables", "menuCat": "Notes", "order": "15", "role": "http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayables", "shortName": "Accrued Liabilities and Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:AccruedLiabilitiesAndOtherPayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Government Loans Payable", "menuCat": "Notes", "order": "16", "role": "http://www.bioessencecorp.com/role/GovernmentLoansPayable", "shortName": "Government Loans Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "17", "role": "http://www.bioessencecorp.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://www.bioessencecorp.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Leases", "menuCat": "Notes", "order": "19", "role": "http://www.bioessencecorp.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:LoanPayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Loan Payables", "menuCat": "Notes", "order": "20", "role": "http://www.bioessencecorp.com/role/LoanPayables", "shortName": "Loan Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:LoanPayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "21", "role": "http://www.bioessencecorp.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "22", "role": "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.bioessencecorp.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Property and Equipment, Net (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.bioessencecorp.com/role/PropertyandEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Intangible Assets, Net (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.bioessencecorp.com/role/IntangibleAssetsNetTables", "shortName": "Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:AccruedLiabilitiesAndOtherPayablestableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Accrued Liabilities and Other Payables (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayablesTables", "shortName": "Accrued Liabilities and Other Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:AccruedLiabilitiesAndOtherPayablestableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Government Loans Payable (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.bioessencecorp.com/role/GovernmentLoansPayableTables", "shortName": "Government Loans Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.bioessencecorp.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.bioessencecorp.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:ScheduleOfMaturitiesOfLoanPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Loan Payables (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.bioessencecorp.com/role/LoanPayablesTables", "shortName": "Loan Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:ScheduleOfMaturitiesOfLoanPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Organization and Description of Business (Details)", "menuCat": "Details", "order": "32", "role": "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAllocatedToLimitedPartners", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "33", "role": "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAllocatedToLimitedPartners", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c42", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment", "menuCat": "Details", "order": "34", "role": "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c42", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Inventory (Details) - Schedule of inventory", "menuCat": "Details", "order": "35", "role": "http://www.bioessencecorp.com/role/ScheduleofinventoryTable", "shortName": "Inventory (Details) - Schedule of inventory", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Security Deposit (Details)", "menuCat": "Details", "order": "36", "role": "http://www.bioessencecorp.com/role/SecurityDepositDetails", "shortName": "Security Deposit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostDepreciationAmortizationAndDepletion", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Property and Equipment, Net (Details)", "menuCat": "Details", "order": "37", "role": "http://www.bioessencecorp.com/role/PropertyandEquipmentNetDetails", "shortName": "Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostDepreciationAmortizationAndDepletion", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment", "menuCat": "Details", "order": "38", "role": "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable", "shortName": "Property and Equipment, Net (Details) - Schedule of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Intangible Assets, Net (Details)", "menuCat": "Details", "order": "39", "role": "http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails", "shortName": "Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible assets", "menuCat": "Details", "order": "40", "role": "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable", "shortName": "Intangible Assets, Net (Details) - Schedule of Intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TaxesPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Taxes Payable (Details)", "menuCat": "Details", "order": "41", "role": "http://www.bioessencecorp.com/role/TaxesPayableDetails", "shortName": "Taxes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TaxesPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "cik00001723059:AccruedLiabilitiesAndOtherPayablestableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:AccruedLitigationLiabilitiesRentNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables", "menuCat": "Details", "order": "42", "role": "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable", "shortName": "Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "cik00001723059:AccruedLiabilitiesAndOtherPayablestableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:AccruedLitigationLiabilitiesRentNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:PaymentsForLoan", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Government Loans Payable (Details)", "menuCat": "Details", "order": "43", "role": "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails", "shortName": "Government Loans Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:PaymentsForLoan", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:FutureMinimumLoanPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Government Loans Payable (Details) - Schedule of future minimum loan payments", "menuCat": "Details", "order": "44", "role": "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable", "shortName": "Government Loans Payable (Details) - Schedule of future minimum loan payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:FutureMinimumLoanPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c57", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:DueFromOfficersOrStockholder", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "45", "role": "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c57", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:DueFromOfficersOrStockholder", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "cik00001723059:EffectiveIncomeTaxRatesReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "46", "role": "http://www.bioessencecorp.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "cik00001723059:EffectiveIncomeTaxRatesReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:DeferredTaxAssetsBadDebtExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets", "menuCat": "Details", "order": "47", "role": "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable", "shortName": "Income Taxes (Details) - Schedule of deferred tax assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:DeferredTaxAssetsBadDebtExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Income Taxes (Details) - Schedule of federal statutory income tax rate and the effective income tax", "menuCat": "Details", "order": "48", "role": "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable", "shortName": "Income Taxes (Details) - Schedule of federal statutory income tax rate and the effective income tax", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R49": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Income Taxes (Details) - Schedule of income tax expense", "menuCat": "Details", "order": "49", "role": "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable", "shortName": "Income Taxes (Details) - Schedule of income tax expense", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Operations (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statements of Operations (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c66", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:LeaseOptionExercisedTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "50", "role": "http://www.bioessencecorp.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c66", "decimals": null, "first": true, "lang": "en-US", "name": "cik00001723059:LeaseOptionExercisedTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Leases (Details) - Schedule of lease costs, lease term and discount rate", "menuCat": "Details", "order": "51", "role": "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable", "shortName": "Leases (Details) - Schedule of lease costs, lease term and discount rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:OperatingLeaseFutureMinimumPaymentsDueInThreeYears", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Leases (Details) - Schedule of lease liabilities", "menuCat": "Details", "order": "52", "role": "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "shortName": "Leases (Details) - Schedule of lease liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:OperatingLeaseFutureMinimumPaymentsDueInThreeYears", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c89", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:LoanAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Loan Payables (Details)", "menuCat": "Details", "order": "53", "role": "http://www.bioessencecorp.com/role/LoanPayablesDetails", "shortName": "Loan Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c89", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:LoanAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "cik00001723059:ScheduleOfMaturitiesOfLoanPayableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c90", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:OperatingLeaseFutureMinimumPaymentsDueInTwoYears", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Loan Payables (Details) - Schedule of maturities of loan payable", "menuCat": "Details", "order": "54", "role": "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable", "shortName": "Loan Payables (Details) - Schedule of maturities of loan payable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "cik00001723059:ScheduleOfMaturitiesOfLoanPayableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c90", "decimals": "0", "first": true, "lang": null, "name": "cik00001723059:OperatingLeaseFutureMinimumPaymentsDueInTwoYears", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c22", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Stockholders\u2019 Deficit (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Stockholders\u2019 Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c22", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://www.bioessencecorp.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "8", "role": "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_bioessen.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "cik00001723059_AccruedLiabilitiesAndOtherPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total accrued liabilities and other payables.", "label": "Accrued Liabilities And Other Payables", "terseLabel": "Total" } } }, "localname": "AccruedLiabilitiesAndOtherPayables", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_AccruedLiabilitiesAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Payables [Abstract]" } } }, "localname": "AccruedLiabilitiesAndOtherPayablesAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_AccruedLiabilitiesAndOtherPayablesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of accrued liabilities and other payables.", "label": "Accrued Liabilities And Other Payables Text Block", "terseLabel": "ACCRUED LIABILITIES AND OTHER PAYABLES" } } }, "localname": "AccruedLiabilitiesAndOtherPayablesTextBlock", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayables" ], "xbrltype": "textBlockItemType" }, "cik00001723059_AccruedLiabilitiesAndOtherPayablestableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued liabilities and other payables [table text block].", "label": "Accrued Liabilities And Other Payablestable Text Block", "terseLabel": "Schedule of accrued liabilities and other payables" } } }, "localname": "AccruedLiabilitiesAndOtherPayablestableTextBlock", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/AccruedLiabilitiesandOtherPayablesTables" ], "xbrltype": "textBlockItemType" }, "cik00001723059_AccruedLiabilitiesandOtherPayablesDetailsScheduleofaccruedliabilitiesandotherpayablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of accrued liabilities and other payables [Abstract]" } } }, "localname": "AccruedLiabilitiesandOtherPayablesDetailsScheduleofaccruedliabilitiesandotherpayablesLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable" ], "xbrltype": "stringItemType" }, "cik00001723059_AccruedLiabilitiesandOtherPayablesDetailsScheduleofaccruedliabilitiesandotherpayablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables [Table]" } } }, "localname": "AccruedLiabilitiesandOtherPayablesDetailsScheduleofaccruedliabilitiesandotherpayablesTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable" ], "xbrltype": "stringItemType" }, "cik00001723059_AccruedLitigationLiabilitiesRentNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued litigation liabilities \u2013 rent, non-current.", "label": "Accrued Litigation Liabilities Rent Noncurrent", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLitigationLiabilitiesRentNoncurrent", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_BadDebtAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Bad debt allowance.", "label": "Bad Debt Allowance", "terseLabel": "Bad debt allowance (in Dollars)" } } }, "localname": "BadDebtAllowance", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_ConcentrationRiskThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Threshold Percentage", "terseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskThresholdPercentage", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_CostOfGoodsSoldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost Of Goods Sold Member", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsSoldMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "domainItemType" }, "cik00001723059_CostOfManufactureServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost Of Manufacture Service Member", "terseLabel": "Cost of manufacture service" } } }, "localname": "CostOfManufactureServiceMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "domainItemType" }, "cik00001723059_CostOfRevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost Of Revenues Abstract", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenuesAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "cik00001723059_CreditCardPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Credit card payable", "label": "Credit Card Payable", "terseLabel": "Credit card payable" } } }, "localname": "CreditCardPayable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_CustomerDeposit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Customer deposit.", "label": "Customer Deposit", "terseLabel": "Customer deposit" } } }, "localname": "CustomerDeposit", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_DeferredTaxAssetsBadDebtExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Bad debt expense.", "label": "Deferred Tax Assets Bad Debt Expense", "terseLabel": "Bad debt expense" } } }, "localname": "DeferredTaxAssetsBadDebtExpense", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_DeferredTaxAssetsDepreciationAndAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation and amortization.", "label": "Deferred Tax Assets Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxAssetsDepreciationAndAmortization", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_DeferredTaxAssetsInventoryImpairmentreversal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory impairment (reversal).", "label": "Deferred Tax Assets Inventory Impairmentreversal", "terseLabel": "Inventory impairment" } } }, "localname": "DeferredTaxAssetsInventoryImpairmentreversal", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_DeferredTaxAssetsOperatingLeaseCharge": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease charge.", "label": "Deferred Tax Assets Operating Lease Charge", "terseLabel": "Operating lease charge" } } }, "localname": "DeferredTaxAssetsOperatingLeaseCharge", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_DueFromOfficerOrStockholders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.", "label": "Due From Officer Or Stockholders", "terseLabel": "Loan amount" } } }, "localname": "DueFromOfficerOrStockholders", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_DueFromOfficersOrStockholder": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of due from officers or stockholder.", "label": "Due From Officers Or Stockholder", "terseLabel": "Officers or stockholder" } } }, "localname": "DueFromOfficersOrStockholder", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_EconomicInjuryDisasterLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Economic Injury Disaster Loan Member", "terseLabel": "Economic Injury Disaster Loan [Member]" } } }, "localname": "EconomicInjuryDisasterLoanMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_EffectiveIncomeTaxRatesReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal corporate income tax.", "label": "Effective Income Tax Rates Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Federal corporate income tax" } } }, "localname": "EffectiveIncomeTaxRatesReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_EquipmentLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equipment Leases Member", "terseLabel": "Equipment leases [Member]" } } }, "localname": "EquipmentLeasesMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "domainItemType" }, "cik00001723059_ExpectedIncomeTaxBenefitFromNOLCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expected income tax benefit from NOL carry-forwards.", "label": "Expected Income Tax Benefit From NOLCarryforwards", "terseLabel": "Expected income tax benefit from NOL carry-forwards" } } }, "localname": "ExpectedIncomeTaxBenefitFromNOLCarryforwards", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_FederalAndCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal And California Member", "terseLabel": "Federal and California [Member]" } } }, "localname": "FederalAndCaliforniaMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_FinanceLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease Member", "terseLabel": "Finance Lease [Member]" } } }, "localname": "FinanceLeaseMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "domainItemType" }, "cik00001723059_FourVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Four Vendor Member", "terseLabel": "Four Vendors [Member]" } } }, "localname": "FourVendorMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_FutureMinimumLoanPaymentsDue": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum loan payments due.", "label": "Future Minimum Loan Payments Due", "totalLabel": "Total" } } }, "localname": "FutureMinimumLoanPaymentsDue", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_FutureMinimumLoanPaymentsDueInFiveYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable": { "order": 5.0, "parentTag": "cik00001723059_FutureMinimumLoanPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum loan payments due In five years.", "label": "Future Minimum Loan Payments Due In Five Years", "terseLabel": "March 31, 2028" } } }, "localname": "FutureMinimumLoanPaymentsDueInFiveYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_FutureMinimumLoanPaymentsDueInFourYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable": { "order": 4.0, "parentTag": "cik00001723059_FutureMinimumLoanPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum loan payments due In four years.", "label": "Future Minimum Loan Payments Due In Four Years", "terseLabel": "March 31, 2027" } } }, "localname": "FutureMinimumLoanPaymentsDueInFourYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_FutureMinimumLoanPaymentsDueInThreeYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable": { "order": 3.0, "parentTag": "cik00001723059_FutureMinimumLoanPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum loan payments due In three years.", "label": "Future Minimum Loan Payments Due In Three Years", "terseLabel": "March 31, 2026" } } }, "localname": "FutureMinimumLoanPaymentsDueInThreeYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_FutureMinimumLoanPaymentsDueInTwoYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable": { "order": 2.0, "parentTag": "cik00001723059_FutureMinimumLoanPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum loan payments due In two years.", "label": "Future Minimum Loan Payments Due In Two Years", "terseLabel": "March 31, 2025" } } }, "localname": "FutureMinimumLoanPaymentsDueInTwoYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_FutureMinimumLoanPaymentsDueThereafter": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable": { "order": 6.0, "parentTag": "cik00001723059_FutureMinimumLoanPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum loan payments due thereafter.", "label": "Future Minimum Loan Payments Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "FutureMinimumLoanPaymentsDueThereafter", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_FutureMinimumLoanPaymentsNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable": { "order": 1.0, "parentTag": "cik00001723059_FutureMinimumLoanPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future Minimum Loan Payments Due, Next Twelve Months.", "label": "Future Minimum Loan Payments Next Twelve Months", "terseLabel": "March 31, 2024" } } }, "localname": "FutureMinimumLoanPaymentsNextTwelveMonths", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_GoingConcernMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern Member", "terseLabel": "Going Concern [Member]" } } }, "localname": "GoingConcernMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going concern [Policy Text Block].", "label": "Going Concern Policy Text Block", "terseLabel": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "cik00001723059_GovernmentLoansPayableCurrentPortion": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Government loans payable - current portion.", "label": "Government Loans Payable Current Portion", "terseLabel": "Government loans payable - current portion (Note 9)" } } }, "localname": "GovernmentLoansPayableCurrentPortion", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "cik00001723059_GovernmentLoansPayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Government Loans Payable (Details) [Line Items]" } } }, "localname": "GovernmentLoansPayableDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_GovernmentLoansPayableDetailsScheduleoffutureminimumloanpaymentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future minimum loan payments [Abstract]" } } }, "localname": "GovernmentLoansPayableDetailsScheduleoffutureminimumloanpaymentsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "stringItemType" }, "cik00001723059_GovernmentLoansPayableDetailsScheduleoffutureminimumloanpaymentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Government Loans Payable (Details) - Schedule of future minimum loan payments [Table]" } } }, "localname": "GovernmentLoansPayableDetailsScheduleoffutureminimumloanpaymentsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable" ], "xbrltype": "stringItemType" }, "cik00001723059_GovernmentLoansPayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Government Loans Payable (Details) [Table]" } } }, "localname": "GovernmentLoansPayableDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_GovernmentLoansPayableNonCurrent": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of government loans payable.", "label": "Government Loans Payable Non Current", "terseLabel": "Government loans payable (Note 9)" } } }, "localname": "GovernmentLoansPayableNonCurrent", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "cik00001723059_HandlingCharge": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Handling charge.", "label": "Handling Charge", "terseLabel": "Handling charge" } } }, "localname": "HandlingCharge", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_ImputedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount.", "label": "Imputed Interest", "negatedLabel": "Less: imputed interest", "terseLabel": "Less: imputed interest" } } }, "localname": "ImputedInterest", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_IncomeTaxBenefitCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax benefit \u2013 current.", "label": "Income Tax Benefit Current", "terseLabel": "Income tax benefit \u2013 current" } } }, "localname": "IncomeTaxBenefitCurrent", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_IncomeTaxesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "localname": "IncomeTaxesDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_IncomeTaxesDetailsScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of federal statutory income tax rate and the effective income tax [Abstract]" } } }, "localname": "IncomeTaxesDetailsScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable" ], "xbrltype": "stringItemType" }, "cik00001723059_IncomeTaxesDetailsScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of federal statutory income tax rate and the effective income tax [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable" ], "xbrltype": "stringItemType" }, "cik00001723059_IncomeTaxesDetailsScheduleofincometaxexpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of income tax expense [Abstract]" } } }, "localname": "IncomeTaxesDetailsScheduleofincometaxexpenseLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable" ], "xbrltype": "stringItemType" }, "cik00001723059_IncomeTaxesDetailsScheduleofincometaxexpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of income tax expense [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleofincometaxexpenseTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable" ], "xbrltype": "stringItemType" }, "cik00001723059_IncomeTaxesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "localname": "IncomeTaxesDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_IncreaseDecreaseAdvanceToSuppliers": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advance to suppliers.", "label": "Increase Decrease Advance To Suppliers", "terseLabel": "Advance to suppliers" } } }, "localname": "IncreaseDecreaseAdvanceToSuppliers", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik00001723059_IncreaseDecreaseInAssetsChangesInAssetsLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Assets Changes In Assets Liabilities Abstract", "terseLabel": "Increase (decrease) in assets: Changes in assets / liabilities:" } } }, "localname": "IncreaseDecreaseInAssetsChangesInAssetsLiabilitiesAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "cik00001723059_IntangibleAssetsNetLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net [Abstract]" } } }, "localname": "IntangibleAssetsNetLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNet" ], "xbrltype": "stringItemType" }, "cik00001723059_IntangibleAssetsNetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net [Table]" } } }, "localname": "IntangibleAssetsNetTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNet" ], "xbrltype": "stringItemType" }, "cik00001723059_IntangibleAssetsNetTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets Net Tables Line Items", "terseLabel": "Intangible Assets, Net [Abstract]" } } }, "localname": "IntangibleAssetsNetTablesLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetTables" ], "xbrltype": "stringItemType" }, "cik00001723059_IntangibleAssetsNetTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Tables) [Table]" } } }, "localname": "IntangibleAssetsNetTablesTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetTables" ], "xbrltype": "stringItemType" }, "cik00001723059_InventoryTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory [Table]" } } }, "localname": "InventoryTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/Inventory" ], "xbrltype": "stringItemType" }, "cik00001723059_LeaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Axis", "terseLabel": "Lease [Axis]" } } }, "localname": "LeaseAxis", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails", "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "stringItemType" }, "cik00001723059_LeaseDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease [Domain]" } } }, "localname": "LeaseDomain", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_LeaseFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Five Member", "terseLabel": "Lease Five [Member]" } } }, "localname": "LeaseFiveMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_LeaseOptionExercisedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term lease option exercised term.", "label": "Lease Option Exercised Term", "terseLabel": "Lease option exercised term" } } }, "localname": "LeaseOptionExercisedTerm", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "cik00001723059_LeaseSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Six Member", "terseLabel": "Lease Six [Member]" } } }, "localname": "LeaseSixMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_LeasesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Line Items]" } } }, "localname": "LeasesDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_LeasesDetailsScheduleofleasecostsleasetermanddiscountrateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of lease costs, lease term and discount rate [Line Items]" } } }, "localname": "LeasesDetailsScheduleofleasecostsleasetermanddiscountrateLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "stringItemType" }, "cik00001723059_LeasesDetailsScheduleofleasecostsleasetermanddiscountrateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of lease costs, lease term and discount rate [Table]" } } }, "localname": "LeasesDetailsScheduleofleasecostsleasetermanddiscountrateTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "stringItemType" }, "cik00001723059_LeasesDetailsScheduleofleaseliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of lease liabilities [Line Items]" } } }, "localname": "LeasesDetailsScheduleofleaseliabilitiesLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "stringItemType" }, "cik00001723059_LeasesDetailsScheduleofleaseliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of lease liabilities [Table]" } } }, "localname": "LeasesDetailsScheduleofleaseliabilitiesTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "stringItemType" }, "cik00001723059_LeasesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "localname": "LeasesDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_LeasesFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases Four Member", "terseLabel": "Leases Four [Member]" } } }, "localname": "LeasesFourMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_LeasesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases One Member", "terseLabel": "Leases One [Member]" } } }, "localname": "LeasesOneMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_LeasesThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases Three Member", "terseLabel": "Leases Three [Member]" } } }, "localname": "LeasesThreeMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_LeasesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases Two Member", "terseLabel": "Leases Two [Member]" } } }, "localname": "LeasesTwoMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_LoanAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loan agreement.", "label": "Loan Agreement", "terseLabel": "Loan agreement" } } }, "localname": "LoanAgreement", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_LoanFromShareholderCurrent": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Loan From Shareholder Current", "terseLabel": "Loan from shareholder (Note 10)" } } }, "localname": "LoanFromShareholderCurrent", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "cik00001723059_LoanPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables Abstract" } } }, "localname": "LoanPayablesAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables Details Line Items", "terseLabel": "Loan Payables [Abstract]" } } }, "localname": "LoanPayablesDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesDetailsScheduleofmaturitiesofloanpayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables (Details) - Schedule of maturities of loan payable [Line Items]" } } }, "localname": "LoanPayablesDetailsScheduleofmaturitiesofloanpayableLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesDetailsScheduleofmaturitiesofloanpayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables (Details) - Schedule of maturities of loan payable [Table]" } } }, "localname": "LoanPayablesDetailsScheduleofmaturitiesofloanpayableTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables (Details) [Table]" } } }, "localname": "LoanPayablesDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables [Abstract]" } } }, "localname": "LoanPayablesLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayables" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables [Table]" } } }, "localname": "LoanPayablesTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayables" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables Tables Line Items", "terseLabel": "Loan Payables [Abstract]" } } }, "localname": "LoanPayablesTablesLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesTables" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payables (Tables) [Table]" } } }, "localname": "LoanPayablesTablesTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesTables" ], "xbrltype": "stringItemType" }, "cik00001723059_LoanPayablesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loan Payables.", "label": "Loan Payables Text Block", "terseLabel": "LOAN PAYABLES" } } }, "localname": "LoanPayablesTextBlock", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayables" ], "xbrltype": "textBlockItemType" }, "cik00001723059_ManufactureServiceRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Manufacture Service Revenue Member", "terseLabel": "Manufacture service revenue" } } }, "localname": "ManufactureServiceRevenueMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "domainItemType" }, "cik00001723059_NetDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Deferred Tax Assets Abstract", "terseLabel": "Net deferred tax assets:" } } }, "localname": "NetDeferredTaxAssetsAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "cik00001723059_NetOperatingLossPerentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Operating Loss Perentage", "terseLabel": "Net operating loss" } } }, "localname": "NetOperatingLossPerentage", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_OneMajorCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Major Customer Member", "terseLabel": "One Major Customer [Member]" } } }, "localname": "OneMajorCustomerMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_OneVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Vendor Member", "terseLabel": "One Vendors [Member]" } } }, "localname": "OneVendorMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_OperatingLeaseFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable": { "order": 4.0, "parentTag": "cik00001723059_UndiscountedCashFlows", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Lease Future Minimum Payments Due In Five Years", "terseLabel": "December 31, 2026", "verboseLabel": "March 31, 2027" } } }, "localname": "OperatingLeaseFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_OperatingLeaseFutureMinimumPaymentsDueInFourYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable": { "order": 3.0, "parentTag": "cik00001723059_UndiscountedCashFlows", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Lease Future Minimum Payments Due In Four Years", "terseLabel": "December 31, 2025", "verboseLabel": "March 31, 2026" } } }, "localname": "OperatingLeaseFutureMinimumPaymentsDueInFourYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_OperatingLeaseFutureMinimumPaymentsDueInSixYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date", "label": "Operating Lease Future Minimum Payments Due In Six Years", "terseLabel": "December 31, 2027" } } }, "localname": "OperatingLeaseFutureMinimumPaymentsDueInSixYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_OperatingLeaseFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable": { "order": 2.0, "parentTag": "cik00001723059_UndiscountedCashFlows", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Lease Future Minimum Payments Due In Three Years", "terseLabel": "December 31, 2024", "verboseLabel": "March 31, 2025" } } }, "localname": "OperatingLeaseFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_OperatingLeaseFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable": { "order": 1.0, "parentTag": "cik00001723059_UndiscountedCashFlows", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Lease Future Minimum Payments Due In Two Years", "terseLabel": "March 31, 2024" } } }, "localname": "OperatingLeaseFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_OperatingLeaseFutureMinimumPaymentsDueThereafter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Lease Future Minimum Payments Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeaseFutureMinimumPaymentsDueThereafter", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_OperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Member", "terseLabel": "Operating Leases [Member]" } } }, "localname": "OperatingLeaseMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "domainItemType" }, "cik00001723059_OperatingLeaseRentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease rent percentage.", "label": "Operating Lease Rent Percentage", "terseLabel": "Rent percentage" } } }, "localname": "OperatingLeaseRentPercentage", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_OperatingLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases Member", "terseLabel": "Operating Leases [Member]" } } }, "localname": "OperatingLeasesMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "domainItemType" }, "cik00001723059_OperatingLeasesPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Leases Payments", "terseLabel": "Monthly rent" } } }, "localname": "OperatingLeasesPayments", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_OrganizationandDescriptionofBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Line Items]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_OrganizationandDescriptionofBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_OwnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership Member", "terseLabel": "Ownership [Member]" } } }, "localname": "OwnershipMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_PPPLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PPPLoan Member", "terseLabel": "PPP Loan [Member]" } } }, "localname": "PPPLoanMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_PaymentsForLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for loans.", "label": "Payments For Loan", "terseLabel": "Public private partnership loans" } } }, "localname": "PaymentsForLoan", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_PercentageOfForgivenAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of forgiven amount.", "label": "Percentage Of Forgiven Amount", "terseLabel": "Percentage of forgiven amount" } } }, "localname": "PercentageOfForgivenAmount", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_PresentValueOfFinanceLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of finance lease liabilities.", "label": "Present Value Of Finance Lease Liabilities", "terseLabel": "Present value of lease liabilities" } } }, "localname": "PresentValueOfFinanceLeaseLiabilities", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_PresentValueOfLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from lease liabilities.", "label": "Present Value Of Lease Liabilities", "terseLabel": "Present value of lease liabilities", "verboseLabel": "Present value of loan payables" } } }, "localname": "PresentValueOfLeaseLiabilities", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_ProceedsFromLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from loan.", "label": "Proceeds From Loan", "terseLabel": "Received loans" } } }, "localname": "ProceedsFromLoan", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_ReclassificationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy reclassifications.", "label": "Reclassifications Policy Text Block", "terseLabel": "Reclassification" } } }, "localname": "ReclassificationsPolicyTextBlock", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "cik00001723059_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_RetainedEarningAccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earning Accumulated Deficit", "terseLabel": "Accumulated deficit (in Dollars)" } } }, "localname": "RetainedEarningAccumulatedDeficit", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_SalesOfGoodsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales of goods [Member]", "label": "Sales Of Goods Member", "terseLabel": "Sales of goods" } } }, "localname": "SalesOfGoodsMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "domainItemType" }, "cik00001723059_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Accrued Liabilities And Other Payables Abstract" } } }, "localname": "ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Deferred Tax Assets Abstract" } } }, "localname": "ScheduleOfDeferredTaxAssetsAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfDepreciationOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Depreciation Of Property And Equipment Abstract" } } }, "localname": "ScheduleOfDepreciationOfPropertyAndEquipmentAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfFederalStatutoryIncomeTaxRateAndTheEffectiveIncomeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Federal Statutory Income Tax Rate And The Effective Income Tax Abstract" } } }, "localname": "ScheduleOfFederalStatutoryIncomeTaxRateAndTheEffectiveIncomeTaxAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfFutureMinimumLoanPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Future Minimum Loan Payments Abstract" } } }, "localname": "ScheduleOfFutureMinimumLoanPaymentsAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfIncomeTaxExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Income Tax Expense Abstract" } } }, "localname": "ScheduleOfIncomeTaxExpenseAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } }, "localname": "ScheduleOfIntangibleAssetsAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfInventoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Inventory [Abstract]" } } }, "localname": "ScheduleOfInventoryAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfLeaseCostsLeaseTermAndDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Lease Costs Lease Term And Discount Rate Abstract" } } }, "localname": "ScheduleOfLeaseCostsLeaseTermAndDiscountRateAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Lease Liabilities Abstract" } } }, "localname": "ScheduleOfLeaseLiabilitiesAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfMaturitiesOfLoanPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Maturities Of Loan Payable Abstract" } } }, "localname": "ScheduleOfMaturitiesOfLoanPayableAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_ScheduleOfMaturitiesOfLoanPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of loan payable.", "label": "Schedule Of Maturities Of Loan Payable Table Text Block", "terseLabel": "Schedule of maturities of loan payable" } } }, "localname": "ScheduleOfMaturitiesOfLoanPayableTableTextBlock", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesTables" ], "xbrltype": "textBlockItemType" }, "cik00001723059_ScheduleOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Abstract" } } }, "localname": "ScheduleOfPropertyAndEquipmentAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_SecurityDepositLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Deposit [Abstract]" } } }, "localname": "SecurityDepositLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SecurityDeposit" ], "xbrltype": "stringItemType" }, "cik00001723059_SecurityDepositTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Deposit [Table]" } } }, "localname": "SecurityDepositTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SecurityDeposit" ], "xbrltype": "stringItemType" }, "cik00001723059_SeniorOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Officer Member", "terseLabel": "Senior Officer [Member]" } } }, "localname": "SeniorOfficerMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_Shareholder1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder1 Member", "terseLabel": "Shareholder [Member]" } } }, "localname": "Shareholder1Member", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_ShippingAndHandlingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shipping and handling costs.", "label": "Shipping And Handling Costs", "terseLabel": "Shipping and handling costs (in Dollars)" } } }, "localname": "ShippingAndHandlingCosts", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "cik00001723059_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_SummaryofSignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_SummaryofSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "localname": "SummaryofSignificantAccountingPoliciesLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "stringItemType" }, "cik00001723059_SummaryofSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "stringItemType" }, "cik00001723059_SummaryofSignificantAccountingPoliciesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summaryof Significant Accounting Policies Tables Line Items", "terseLabel": "Summary of Significant Accounting Policies [Abstract]" } } }, "localname": "SummaryofSignificantAccountingPoliciesTablesLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "cik00001723059_SummaryofSignificantAccountingPoliciesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Tables) [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesTablesTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "cik00001723059_TaxBenefit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit.", "label": "Tax Benefit", "terseLabel": "Tax benefit" } } }, "localname": "TaxBenefit", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_TaxPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tax Payable Abstract" } } }, "localname": "TaxPayableAbstract", "nsuri": "http://www.bioessencecorp.com/20230331", "xbrltype": "stringItemType" }, "cik00001723059_TaxPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Payable [Text Block]", "label": "Tax Payable Text Block", "terseLabel": "TAXES PAYABLE" } } }, "localname": "TaxPayableTextBlock", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/TaxesPayable" ], "xbrltype": "textBlockItemType" }, "cik00001723059_TaxableIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Taxpayer's taxable percentage.", "label": "Taxable Income Percentage", "terseLabel": "Taxable income percentage" } } }, "localname": "TaxableIncomePercentage", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_TaxesPayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes Payable Details Line Items", "terseLabel": "Tax Payable [Abstract]" } } }, "localname": "TaxesPayableDetailsLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/TaxesPayableDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_TaxesPayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes Payable (Details) [Table]" } } }, "localname": "TaxesPayableDetailsTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/TaxesPayableDetails" ], "xbrltype": "stringItemType" }, "cik00001723059_TaxesPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tax Payable [Abstract]" } } }, "localname": "TaxesPayableLineItems", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/TaxesPayable" ], "xbrltype": "stringItemType" }, "cik00001723059_TaxesPayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes Payable [Table]" } } }, "localname": "TaxesPayableTable", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/TaxesPayable" ], "xbrltype": "stringItemType" }, "cik00001723059_ThreeVendorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Vendors Member", "terseLabel": "Three Vendors [Member]" } } }, "localname": "ThreeVendorsMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_TotalSalesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total sales percentage,", "label": "Total Sales Percentage", "terseLabel": "Total sales percentage" } } }, "localname": "TotalSalesPercentage", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "cik00001723059_TwoVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Vendor Member", "terseLabel": "Two Vendors [Member]" } } }, "localname": "TwoVendorMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "cik00001723059_UndiscountedCashFlows": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's discounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Undiscounted Cash Flows", "terseLabel": "Total undiscounted cash flows", "totalLabel": "Total undiscounted cash flows" } } }, "localname": "UndiscountedCashFlows", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable", "http://www.bioessencecorp.com/role/ScheduleofmaturitiesofloanpayableTable" ], "xbrltype": "monetaryItemType" }, "cik00001723059_WarehouseAndOfficeLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warehouse And Office Lease Member", "terseLabel": "Warehouse and Office Lease [Member]" } } }, "localname": "WarehouseAndOfficeLeaseMember", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "domainItemType" }, "cik00001723059_fixedAssetsObtainedInExchangeForNewFinancingLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "fixed assets obtained in exchange for new financing lease liabilities\r \n.", "label": "fixed Assets Obtained In Exchange For New Financing Lease Liabilities", "terseLabel": "Fixed assets obtained in exchange for new finance lease liabilities" } } }, "localname": "fixedAssetsObtainedInExchangeForNewFinancingLeaseLiabilities", "nsuri": "http://www.bioessencecorp.com/20230331", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioessencecorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r203", "r495", "r554", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r227", "r228", "r229", "r230", "r270", "r351", "r391", "r407", "r408", "r464", "r465", "r466", "r467", "r468", "r473", "r474", "r487", "r493", "r496", "r500", "r553", "r568", "r569", "r570", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r227", "r228", "r229", "r230", "r270", "r351", "r391", "r407", "r408", "r464", "r465", "r466", "r467", "r468", "r473", "r474", "r487", "r493", "r496", "r500", "r553", "r568", "r569", "r570", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r203", "r495", "r554", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r201", "r353", "r385", "r386", "r387", "r388", "r389", "r390", "r476", "r494", "r499", "r523", "r549", "r550", "r554", "r575" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r201", "r353", "r385", "r386", "r387", "r388", "r389", "r390", "r476", "r494", "r499", "r523", "r549", "r550", "r554", "r575" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r227", "r228", "r229", "r230", "r268", "r270", "r276", "r277", "r278", "r350", "r351", "r391", "r407", "r408", "r464", "r465", "r466", "r467", "r468", "r473", "r474", "r487", "r493", "r496", "r500", "r503", "r548", "r553", "r569", "r570", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r227", "r228", "r229", "r230", "r268", "r270", "r276", "r277", "r278", "r350", "r351", "r391", "r407", "r408", "r464", "r465", "r466", "r467", "r468", "r473", "r474", "r487", "r493", "r496", "r500", "r503", "r548", "r553", "r569", "r570", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r173", "r271", "r518", "r543" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable", "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable", "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable", "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r209", "r210", "r211" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r173", "r271", "r518", "r519", "r543" ], "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable", "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable", "http://www.bioessencecorp.com/role/ScheduleoffutureminimumloanpaymentsTable", "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable" ], "xbrltype": "stringItemType" }, "srt_StatisticalDisclosureForBanksAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statistical Disclosure for Banks [Abstract]" } } }, "localname": "StatisticalDisclosureForBanksAbstract", "nsuri": "http://fasb.org/srt/2023", "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r544", "r564" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued liabilities and other payables (Note 8)" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r498" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r204", "r205" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r47", "r135", "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Intangible assets useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r69", "r498", "r578" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r280", "r281", "r282", "r405", "r540", "r541", "r542", "r559", "r579" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "ADDITIONAL PAID IN CAPITAL" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r4", "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AdvancesOnInventoryPurchases": { "auth_ref": [ "r531" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.", "label": "Advances on Inventory Purchases", "terseLabel": "Advance to suppliers" } } }, "localname": "AdvancesOnInventoryPurchases", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense (in Dollars)" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r4", "r40", "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible of assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r137", "r157", "r183", "r195", "r199", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r307", "r309", "r320", "r371", "r429", "r498", "r510", "r551", "r552", "r566" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r130", "r141", "r157", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r307", "r309", "r320", "r498", "r551", "r552", "r566" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r157", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r307", "r309", "r320", "r551", "r552", "r566" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "NONCURRENT ASSETS" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BankOverdrafts": { "auth_ref": [ "r18", "r48" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.", "label": "Bank Overdrafts", "terseLabel": "Bank overdraft" } } }, "localname": "BankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r60", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r27", "r133", "r478" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r27", "r84", "r154" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH & EQUIVALENTS, END OF PERIOD", "periodStartLabel": "CASH & EQUIVALENTS, BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r84" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET DECREASE IN CASH & EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of non-cash financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r58", "r372", "r416" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r501", "r502", "r503", "r505", "r506", "r507", "r508", "r540", "r541", "r559", "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "COMMON - STOCK" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r68", "r417" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r68", "r417", "r435", "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r68", "r374", "r498" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock $0.0001 par value; authorized shares 100,000,000; issued and outstanding shares 33,009,000 as of March 31, 2023 and December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r477", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer Software [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r32", "r34", "r53", "r54", "r203", "r472" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r32", "r34", "r53", "r54", "r203", "r397", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r32", "r34", "r53", "r54", "r203", "r472", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r32", "r34", "r53", "r54", "r203" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r32", "r34", "r53", "r54", "r203", "r472" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostDepreciationAmortizationAndDepletion": { "auth_ref": [ "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service.", "label": "Cost, Depreciation, Amortization and Depletion", "terseLabel": "Depreciation" } } }, "localname": "CostDepreciationAmortizationAndDepletion", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r80", "r157", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r320", "r551" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Total cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r102", "r296", "r302", "r539" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Income tax expense \u2013 current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r33", "r203" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Government Loans Payable [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r97", "r156", "r240", "r246", "r247", "r248", "r249", "r250", "r251", "r256", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "GOVERNMENT LOANS PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r64", "r65", "r104", "r106", "r159", "r241", "r242", "r243", "r244", "r245", "r247", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r327", "r488", "r489", "r490", "r491", "r492", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r55", "r56", "r241", "r327", "r489", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Paycheck protection program loan" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r20", "r242" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Annual interest, percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r159", "r241", "r242", "r243", "r244", "r245", "r247", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r327", "r488", "r489", "r490", "r491", "r492", "r537" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r4", "r102", "r124", "r301", "r302", "r539" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Total income tax expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofincometaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r556" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r51", "r557" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "Net deferred tax assets (in Dollars)" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilitiesDisclosuresTextBlock": { "auth_ref": [ "r8", "r57", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity.", "label": "Deposit Liabilities Disclosures [Text Block]", "terseLabel": "SECURITY DEPOSIT" } } }, "localname": "DepositLiabilitiesDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SecurityDeposit" ], "xbrltype": "textBlockItemType" }, "us-gaap_Deposits": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.", "label": "Deposits", "terseLabel": "Security deposit" } } }, "localname": "Deposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SecurityDepositDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r527" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Security deposit (Note 4)" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r4", "r46" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Interest rate, percentage" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r149", "r165", "r166", "r167", "r168", "r169", "r174", "r176", "r178", "r179", "r180", "r181", "r318", "r319", "r368", "r382", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic and diluted net loss per share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r149", "r165", "r166", "r167", "r168", "r169", "r176", "r178", "r179", "r180", "r181", "r318", "r319", "r368", "r382", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (Loss) per Share (EPS)" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r158", "r288", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Federal statutory income tax expense (benefit) rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r555", "r558" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r555", "r558" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleoffederalstatutoryincometaxrateandtheeffectiveincometaxTable" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r10", "r128", "r145", "r146", "r147", "r160", "r161", "r162", "r164", "r170", "r172", "r182", "r213", "r214", "r267", "r280", "r281", "r282", "r297", "r298", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r321", "r322", "r323", "r324", "r325", "r326", "r341", "r392", "r393", "r394", "r405", "r458" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Shareholder, percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements and Disclosures" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r7", "r11" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value (\u201cFV\u201d) of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r331", "r335", "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r330", "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r330" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities (Note 12)" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r330" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities (Note 12)" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r339", "r497" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate \u2013 Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r338", "r497" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted Average Remaining Lease Term - Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "durationItemType" }, "us-gaap_FinancingInterestExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents interest incurred for borrowed money which was used to produce goods or render services.", "label": "Financing Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "FinancingInterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r136", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Amortization expense, year 4" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Amortization expense, year 3" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Amortization expense, year 2" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Amortization expense, year 1" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r221", "r223", "r224", "r226", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r91", "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets, total" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r41", "r44" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r91", "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r81", "r440" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r79", "r157", "r183", "r194", "r198", "r200", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r320", "r485", "r551" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r1", "r77", "r108", "r183", "r194", "r198", "r200", "r369", "r380", "r485" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r158", "r284", "r289", "r290", "r294", "r299", "r304", "r305", "r306", "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r125", "r171", "r172", "r186", "r287", "r300", "r384" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r144", "r285", "r286", "r290", "r291", "r293", "r295", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r3" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r3" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "auth_ref": [ "r535" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.", "label": "Increase (Decrease) in Accrued Taxes Payable", "terseLabel": "Taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerDeposits": { "auth_ref": [ "r113" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.", "label": "Increase (Decrease) in Customer Deposits", "terseLabel": "Customer deposit" } } }, "localname": "IncreaseDecreaseInCustomerDeposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r3" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Accrued liabilities and other payables" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r535" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Payment on lease liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r3" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r222", "r225" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r42", "r93" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS, NET" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r39", "r43" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net (Note 6)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseInterestBearingLiability": { "auth_ref": [ "r525", "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on interest-bearing liability.", "label": "Interest Expense, Interest-Bearing Liability", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseInterestBearingLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/LoanPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r150", "r152", "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest on government loans" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r38", "r530" ], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofinventoryTable": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Inventory Adjustments", "negatedLabel": "Less: inventory impairment allowance" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r528" ], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofinventoryTable": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods \u2013 health supplements" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Abstract]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/Inventory" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r139", "r479", "r498" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bioessencecorp.com/role/ScheduleofinventoryTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net (Note 3)", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet", "http://www.bioessencecorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r115", "r132", "r138", "r215", "r216", "r217", "r352", "r481" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r529" ], "calculation": { "http://www.bioessencecorp.com/role/ScheduleofinventoryTable": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r334", "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease option" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease costs, lease term and discount rate" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]", "verboseLabel": "Leaseholder improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable", "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r157", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r308", "r309", "r310", "r320", "r415", "r484", "r510", "r551", "r566", "r567" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r73", "r107", "r376", "r498", "r538", "r545", "r560" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r131", "r157", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r308", "r309", "r310", "r320", "r498", "r551", "r566", "r567" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r12", "r61", "r62", "r63", "r66", "r157", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r308", "r309", "r310", "r320", "r551", "r566", "r567" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "NONCURRENT LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityPeriodicPayment": { "auth_ref": [ "r15" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments of both interest and principal.", "label": "Line of Credit Facility, Periodic Payment", "terseLabel": "Installment payments including principal and interest" } } }, "localname": "LineOfCreditFacilityPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Loan payables (Note 13)" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansReceivableBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable.", "label": "Loans Receivable, Basis Spread on Variable Rate", "terseLabel": "Interest percentage" } } }, "localname": "LoansReceivableBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r21" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Loan payables (Note 13)" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r151" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r85", "r86" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r78", "r86", "r109", "r129", "r142", "r143", "r147", "r157", "r163", "r165", "r166", "r167", "r168", "r171", "r172", "r177", "r183", "r194", "r198", "r200", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r319", "r320", "r381", "r437", "r456", "r457", "r485", "r509", "r551" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow", "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement", "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAllocatedToLimitedPartners": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of net income allocated to limited partners.", "label": "Net Income (Loss) Allocated to Limited Partners", "terseLabel": "Net losses (in Dollars)" } } }, "localname": "NetIncomeLossAllocatedToLimitedPartners", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Financial expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office furniture [Member]", "verboseLabel": "Office furniture and equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable", "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r183", "r194", "r198", "r200", "r485" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r336", "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r561" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r330" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities (Note 12)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r330" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities (Note 12)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r332", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Monthly payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r329" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r339", "r497" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate - Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r338", "r497" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted Average Remaining Lease Term - Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleasecostsleasetermanddiscountrateTable" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Income tax (in Dollars)" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r82" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedLabel": "Other expense" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r383", "r438", "r469", "r470", "r471" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expenses)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "totalLabel": "Other expenses, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r25" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Repayment of finance lease liabilities" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r67", "r266" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r67", "r417" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r67", "r373", "r498" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock $0.0001 par value; authorized shares 10,000,000" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r140", "r218", "r219", "r480" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r24" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Loan from shareholder" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts": { "auth_ref": [ "r533", "r534", "r536" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.", "label": "Proceeds from (Repayments of) Bank Overdrafts", "terseLabel": "Bank overdraft" } } }, "localname": "ProceedsFromRepaymentsOfBankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable", "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r94", "r119", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/PropertyandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r95", "r134", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r370", "r379", "r498" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net (Note 5)", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet", "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r5", "r119", "r122", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/PropertyandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "durationItemType" }, "us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Public Utility, Property, Plant and Equipment [Line Items]" } } }, "localname": "PublicUtilityPropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilityPropertyPlantAndEquipmentTable": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Public Utility, Property, Plant and Equipment [Table]" } } }, "localname": "PublicUtilityPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r269", "r345", "r346", "r410", "r411", "r412", "r413", "r414", "r434", "r436", "r463" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r345", "r346", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails", "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactionsDetails", "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r269", "r345", "r346", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r410", "r411", "r412", "r413", "r414", "r434", "r436", "r463", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r342", "r343", "r344", "r346", "r347", "r402", "r403", "r404", "r441", "r442", "r443", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfBankDebt": { "auth_ref": [ "r26" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to settle a bank borrowing during the year.", "label": "Repayments of Bank Debt", "negatedLabel": "Repayment of government loans" } } }, "localname": "RepaymentsOfBankDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r534" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "Repayments of Debt", "negatedLabel": "Repayment of loan payables" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r70", "r98", "r375", "r395", "r396", "r400", "r418", "r498" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r160", "r161", "r162", "r164", "r170", "r172", "r213", "r214", "r280", "r281", "r282", "r297", "r298", "r311", "r313", "r314", "r316", "r317", "r392", "r394", "r405", "r579" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "ACCUMULATED DEFICIT" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionAllowances": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition for sales allowances.", "label": "Revenue Recognition, Allowances [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionAllowances", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r439", "r475", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r148", "r157", "r184", "r185", "r193", "r196", "r197", "r201", "r202", "r203", "r212", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r320", "r369", "r551" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r203", "r520" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income tax expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of federal statutory income tax rate and the effective income tax" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r41", "r44", "r354" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r41", "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of future minimum loan payments" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/GovernmentLoansPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.", "label": "Public Utility Property, Plant, and Equipment [Table Text Block]", "terseLabel": "Schedule of depreciation of property and equipment" } } }, "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDepositLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.", "label": "Security Deposit Liability", "terseLabel": "security deposits" } } }, "localname": "SecurityDepositLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r192", "r202", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.", "label": "Selling Expense", "terseLabel": "Selling" } } }, "localname": "SellingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "March 31, 2028 (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofleaseliabilitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": { "auth_ref": [ "r272", "r273", "r279" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.", "label": "Share-Based Payment Arrangement, Forfeiture [Policy Text Block]", "terseLabel": "Share-based Compensation" } } }, "localname": "ShareBasedCompensationForfeituresPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "terseLabel": "Shipping and Handling Costs" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r87", "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r10", "r23", "r128", "r145", "r146", "r147", "r160", "r161", "r162", "r164", "r170", "r172", "r182", "r213", "r214", "r267", "r280", "r281", "r282", "r297", "r298", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r321", "r322", "r323", "r324", "r325", "r326", "r341", "r392", "r393", "r394", "r405", "r458" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r160", "r161", "r162", "r182", "r353", "r398", "r406", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r436", "r439", "r440", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r458", "r504" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement", "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r160", "r161", "r162", "r182", "r353", "r398", "r406", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r436", "r439", "r440", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r458", "r504" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement", "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r68", "r71", "r72", "r89", "r419", "r435", "r459", "r460", "r498", "r510", "r538", "r545", "r560", "r579" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet", "http://www.bioessencecorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Data:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Taxes payable (Note 7)" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "auth_ref": [ "r65", "r105", "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.", "label": "Taxes Payable", "terseLabel": "Sales tax and payroll tax payable" } } }, "localname": "TaxesPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/TaxesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r110", "r111", "r112", "r206", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademark [Member]" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ScheduleofIntangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r35", "r36", "r37", "r117", "r118", "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r175", "r180" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r174", "r180" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic and diluted weighted average shares outstanding (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bioessencecorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(e)", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(m)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r514": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r515": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r516": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org//705/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "980", "URI": "https://asc.fasb.org//1943274/2147481834/980-20-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 74 0001213900-23-039043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-039043-xbrl.zip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